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INTRODUCTION
MICROCAPSULES 1
Microcapsules  are  small  particles  of  solids  or  small  droplets  of  liquids 
surrounded by a wall of natural polymer and also synthetic polymer films of 
varying thickness and degree of permeability in the size range of about 
0.1-1000µm.  The  purpose   for  microencapsulation   are  environmental 
protection  gastric irritation reduction, liquid-solid conversion ,taste–odour 
masking separation of   incompatibilities,  controlling sustaining action of 
active substances minimizing and eliminating side effects.
Microencapsulation  provides  many  possibilities  for  producing 
improved forms of pharmaceutical and diagnostic aids. History of micro 
encapsulation says CREATION OF LIVING CELLS IS THE BEGINNING 
OF MICRO ENCAPSULATION. Most of the one celled animals are living 
examples of micro encapsulation.
CONTROLLED–RELEASE DRUG-DELIVERY 2,3,4,5,6,7 
        The goal of any drug delivery system is to provide a therapeutic  
amount of drug to the proper site in the body to achieve promptly and then 
maintain the desired drug concentration. That is, the drug- delivery system 
should deliver drug at a rate dictated by the needs of the body over a 
specified period of treatment.  This idealized objective points  to the two 
aspects most important to drug delivery,  namely,  spatial placement and 
temporal delivery of a drug .Spatial placement relates to targeting a drug 
to a specific organ or tissue, while temporal delivery refers to controlling 
the rate of drug delivery to the target tissue.  An appropriately designed 
controlled - release drug – delivery system can be a major advance toward 
solving  these  two  problems.  It  is  for  this  reason  that  the  science  and 
technology  responsible  for  development  of  controlled-  release 
pharmaceuticals has been, and continues to be the focus of a great deal of 
attention in both industrial and academic laboratories. 
             In the recent years, considerable attention has been focused on 
the development of new drug delivery systems. The therapeutic efficiency 
and  safety  of  drugs  administered  by  conventional  methods  can  be 
improved by more precise spatial and temporal placement within the body,  
thereby reducing both the size and number of doses, through a controlled 
drug delivery.
In  the  simplest  model  (Figure  1) the  fate  of  the  drug  may  be 
characterized by a single compartment, which is described by the plasma 
concentration of drug with time.
Figure 1   A simple pharmacokinetic model3
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Controlled-release  drug  delivery  produce  a  well-characterized  and 
reproducible dosage form that controls drug entry into the body within the 
specifications of  the required drug delivery profile.  Conventional  tablets 
fails in the lack of characterization and control of absorption.
DEFINITION AND TERMINOLOGY
Delivery rates   from temporal controlled release system may be 
characterized in terms of their kinetics and physical processes of particular 
interest are zero order systems for which the release of drug is constant 
with  time. Zero order systems can be in principle allow for selection of 
precise. Efficacious plasma levels after titration for inter-individual variation 
with a controlled constant drug input, greater selectivity of drug action and 
reduced  toxicity  might  be  achieved  by  avoiding  successive  peaks  and 
valleys of drug concentration associated with conventional therapy. This 
concept of plasma steady state or zero-order pharmacology will have far 
reaching implications in the ultimate goal of optimum drug therapy.
          Unfortunately, there is no universal agreement in the use of such 
terms, the products designed   to provide an extended duration of action in 
comparison to single dose can be classified into three main categories. 
Figure 2
Figure 2 Different plasma release profiles resulting from
various extended duration products4-6
1. Sustained-release products
These  are  drug  delivery  systems  designed  to  provide  an  initial 
therapeutic dose that is made available upon administration, followed by 
maintenance of activity over an extended period of time.
2. Prolonged release products: 
This term refers to preparation designed to provide a slow release 
of  a  drug  at  a  rate  which  will  provide  a  longer  duration  of  action  in 
comparison to the normal single dose. Prolonged release products may 
show a relatively delayed onset of action due to their overall slow release 
rate
3. Repeat action preparations:
These are products designed to release an initial dose immediately 
after administration, followed by a second and a third dose after the same 
period of time has elapsed. 
CLASSIFICATION OF CONTROL DRUG DELIVERY SYSTEM
Controlled (Zero- order) drug release is schematically illustrated in Figure 
3
Figure 3 Schematic Illustration of Controlled drug release7
Drug concentration levels in the blood plasma are not necessarily equal to 
the quantity of drug released from a device because drug absorption is 
determined largely by its solubility in tissues and availability of local blood 
flow  in  the  tissues.  Even  if  the  drug  concentration  in  plasma  were  to 
remain reasonably constant, small short-term fluctuations would always be 
seen  due  to  factors  such  as  physical  activities,  emotional  stimulation 
(stress), eating and sleeping.
The design and  fabrication  of   oral  CR systems  are  reviewed 
under the following classification.
Oral controlled release system
a. Dissolution  control        a.  Density based systems 
 a. Intestinal release     
b. Diffusion control b. Size- based systems  b.      Colonic release
c. Dissolution and diffusion c.  Bio-adhesive  based 
systems 
control based system.
d. Ion- exchange resins
e. Osmotically controlled devices
f. Slow dissolving salts or complexes
g. PH-independent formulations
 ADVANTAGES AND DISADVANTAGES 
The  goal  of  oral  CR  products  is  to  achieve  better  therapeutic 
success than with conventional dosage forms of the same drug. This goal 
is  realized  by  improving  the  pharmacokinetic  profile  as  well  as  patient 
convenience and compliance in therapy. This improvement is perhaps the 
major  reason  for  so  much  attention  being  focused  on  drugs  used  in 
chronic therapy.
The  complexity  of  the  variable  and  regulations  involved  in  the 
manufacture of drug products necessitates that a careful risk and benefit 
analysis should be conducted before a final decision is made to develop a 
controlled release product.
ADVANTAGES OF EXTENDED RELEASE PRODUCTS.
From  the  therapeutic  point  of  view  extended  release  products 
provide three main advantages.
1. Elimination of peaks and valleys in plasma levels so that drug 
concentration is maintained constant over a long period of time. This is 
highly desirable in case of antibiotics, anticonvulsants, hypoglycemic and 
hypotensive  agents  and number  of  other  medicinal  agents  used in  the 
treatment of chronic ailments.
2. Long  acting  products  enforce  patient  compliance  due  to 
convenience of dosing regimen i.e.,  only two tablets or capsules a day 
instead of one or two every four to six hours.
3. Oral  CR  formulations  are  valuable  for  maintaining  plasma 
levels  within  a narrow therapeutic  range.  In  fact   a  valid  rationales for 
formulating drugs with  half  life of  over 8 hours as CR formulation is to 
maintain  plasma  drug  levels  within  a  narrow  therapeutic  range.  By 
reducing the rate of drug release, it is possible to produce a flatter plasma-
level curve and avoid toxic drug concentration in the body.
DISADVANTAGES OF EXTENDED RELEASE PRODUCTS
Controlled  release  products  must  be  viewed  as  multidose 
preparations, which bear the following consequences of their use.
1. Overdose or dose dumping
Being  multidose  preparation  there  is  always  the  possibility  of 
sudden release of the total dose administered, which may result in some 
toxic manifestations or side effects.
2. Loss of flexibility in dosage
It is very difficult to adjust the dose of extended release product to 
the patient’s response. In many cases an induction of therapy needs to be 
achieved by a single dosing regimen followed by careful monitoring while 
under a treatment with extended release preparations.
3. Side effects
Extended  duration  of  action  also  produce  long  duration  of  side 
effects, especially if the patient happens to be hypersensitive to the given 
medication. 
CHOICE OF DOSAGE FORM 8,9,10,11
After careful evaluation of a drug candidate for potential formulation 
in to an extended release product, the decision with respect to the choice 
of an optimal drug delivery system is determined by the following factors. 
1. Physical and Chemical properties of drug
The physical and Chemical properties of the drug includes stability,  
solubility,  partitioning  characteristics,  its  ability  to  form  stable  insoluble 
derivatives  or  salts,  its  interaction   with  coating  materials  or  polymeric 
matrices  and  other  potential  incompatibilities.eg.  Absorption  of  poorly 
soluble drug is often dissolution rate limited and are not good candidates 
of  oral  CR formulations drugs with  good aqueous solubility make good 
candidate for CR dosage forms.
2. Desired extension of duration
Obviously a drug product intended to release the active ingredient 
over a period of days cannot be formulated in an oral dosage form, simply 
because  of  the  motility  of  the  GIT.  Only  controlled  release  products 
designed to release their content of active ingredient within 12-24 hours 
can be formulated in a dosage form suitable for oral administration.
3. Total dosage administered
     In  spite  of  the  fact  that  a  lower  dose  may  be  needed  for  a 
controlled  release  product  as  compared  to  single  dosing  regimen, 
extended duration products are multi dose preparation and therefore the 
total mass of drug included in the formulation may determine the type of 
dosage form for a given site of action.
4 Route of administration
Generally speaking the route of administration determines the type 
of drug delivery system and therefore the manipulative process of choice. 
A general classification is extended release drug delivery systems and the 
most appropriate manipulation technique are shown in figure 4.
Limitations
Not all  drugs tend themselves to the formulation of an extended 
duration product. The most important factors to be considered in choice of 
drug candidate for controlled release preparation are as follows :
 Biological half life
 Therapeutic dose
 Blood levels and pharmacological  activity
 Stability the wide pH range GI enzymes and flora.
 First - pass metabolism
Chapter 1                            
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Figure 4 Extended release dosage forms and corresponding methods of technical manipulation4
       
EXTENDED RELEASE DRUG DELIVERY SYSTEM
ENTERAL (ORAL) PARENTERAL
SOLID DOSAGE FORMS
• Hard gelatin 
capsules
• Tablets.
∗   Cored coated
∗ Sandwich 
(layered)
• Matrix 
LIQUID DOSAGE FORMS
• Suspensions NON –STERILE DOSAGE 
FORMS
• Transdermal 
devices
• Vaginal rings
STERILE DOSAGE FORMS
• Injections (i.m., s.c..)
• Implants
• Intra- uterine devices
• Ocular devices
• Osmatic pumps
o INSOLUBLE 
SALTS
o DERIVATIZATIO
N
o ION-EXCHANGE 
RESINS
Membrane barrier
Matrix incorporationo Nanoencapsulation
o Matrix embedding
o Insoluble salts
o Derivatization
o Polymer grafting
o MICROENCAPSULATION
o COATING TECHNIQUES
o MATRIX EMBEDDING
o COMPRESSION
o INSOLUBLE SALTS
o DERIVATIZATION
o ION EXCHANGE RESINS
METHODS AND APPROACHES OF TECHNICAL MANIPULATION
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TARGETED DRUG DELIVERY  15
The principle behind targeted drug delivery system is to obtain a 
desirable therapeutic effect, i.e. the correct amount of drug should be 
transported & delivered to the site of action with subsequent control of 
drug  input  rate.  By  targeted  drug  delivery,  we  can  get  improve 
therapeutic  efficacy,  reduction  in  side  effects  &  optimized  dosing 
regimen.
CONCEPTS OF TARGETING
The  concepts  of  designing  specified  delivery  system  is  to 
achieve  selective  drug  targeting  has  been  originated  from  the 
perception  of  Paul  Ehrlich,  who  proposed  drug  delivery  to  be  as  a 
“magic bullets” describing targeted drug delivery as an event where, a 
carrier-complex/conjugate, delivers drug exclusively to the pre selected 
target cells in specific manner.
Figure 5 Principle and Rationale of drug Targeting
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Target is signified if target compartments are distinguished from 
other compartments, where toxicity may occur & if active drug could be 
predominantly placed in the proximity of target site.
CARRIERS
Carriers  are  one  of  the  most  important  entities  essentially 
required for successful  transportation of the loaded drugs. They are 
drug vectors, which sequester, transport & retain drug enroute, which 
elute or deliver within or in the vicinity of the target carriers can do so 
utilities  through  inherent  characteristics  or  acquired,  to  interact 
selectively  &  biological  targets  or  otherwise  they are  engineered  to 
release the drug in the proximity of target cells lines demanding optimal 
pharmacological action (therapeutic index).
Figure 6 Schematic Illustration of the requirement of carriers 
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   Based on nature of their origin, they are categorized as endogenous 
(low density lipoprotein, high density lipoprotein, chylomicrons, serum 
albumin,  erythrocytes)  &  exogenous  (microparticulate,  soluble 
polymeric & biodegradable polymeric drug carriers)
LEVELS OF DRUG TARGETING
The various approaches of vectoring the drug to the target site 
can be broadly classified as 
1. Passive targeting 
2. Inverse targeting
3. Active  targeting  (  ligand  medicated  targeting&  physical 
targeting)
4. Dual targeting
5. Double targeting
6. Combination targeting.
ADVANTAGES
1. The drug should be transported & delivered to site of action.
2. The control of drug input rate.
3. The target  oriented drug administration  with  improvements  of 
therapeutic efficiency
4. Reduction in side effects.
5. Optimized dosing regimen.
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6. Target drug delivery implies for selective & effective localization 
of pharmacologically active moiety at pre identified targets.
7. Restricted  distribution  of  parent  drug  to  non  target  site  with 
effective accessibility to target sites.
DISADVANTAGES
1. Rapid  clearance  of  targeted 
systems especially antibody targeted carriers.
2. Immune  reactions  against 
intravenous administered carrier systems.
3. Target tissue heterogeneity
4. Problems  of  insufficient 
localization of targeted system into tumor cells.
5. Down regulation &  sloughing of 
surface epitopes
6. Diffusion  &  redistribution  of 
released drug leading to non-specific accumulation.
21
COLON  DRUG DELIVERY16
The colon drug delivery has a number of important implications 
in  the  field  of  pharmacotherapy.  Various  diseases  including 
Inflammatory Bowel Diseases (IBD) can be effectively treated by the 
local  delivery  of  drugs  to  the  large  intestine.  By  this  technique, 
absorption of the drug from the stomach and small  intestine can be 
minimized   until the drug reaches the large intestine. The treatment of 
large  intestine  disorders,  such  as  Crohn’s  disease,  irritable  bowel 
syndrome,  colitis,  colon  cancer  and local  infectious  disease were  a 
high concentration of active drug is needed, can be improved by colon 
specific  drug  delivery  systems  employing  various  mechanism  of 
release  Table  1.  The  disease  state  can  also  potentially  alter  the 
delivery and absorption characteristics of drug from the colon.
Table 1 Colon Targeting disease,drug and sites
Target sites Diseases condition Drugs and active agents
Topical action Inflammatory Bowel disease, irritable bowel disease and 
Crohn’s disease
Hydrocortisone, Budenoside, 
Prednisolone, sulfasalazine, 
Olsalazine, Mesalzine and 
Balsalazide
Local action
Chronic pancreatitits, 
pancreatomy  and cystic 
fibrosis ,colorectal cancer
Digestive enzyme 
supplements
5- Flourouracil
Systemic To prevent gastric irritation NSAIDs
22
action
To prevent first pass 
Metabolism of orally 
ingested drugs
Oral delivery of peptides
Oral delivery of vaccines
Steroids
Insulin
Typhoid
ANATOMIC  AND  PHYSIOLOGICAL  CONSIDERATIONS  FOR 
COLONIC DRUG DELIVERY
Irrespective  of  therapy desired  for  local  (colonic)  or  systemic 
delivery of drug, the development and aim of the drug delivery to colon,  
remains  same.   Firstly,  the  drug  must  not  be  absorbed  from other 
regions of GIT. Thirdly, it should, only suffer negligible degradation in 
the small intestine lumen. Secondly, the release of the drug in colon 
should be at quantitatively controlled rate and the released drug should 
be  absorbed  from  the  lumen  of  the  large  intestine  without  any 
appreciable degradation in the lumen. In order to meet these priories, a 
thorough knowledge of the anatomy and physiology of GIT is required. 
Figure 7 and  Table 2 categorically presents some important properties 
of human GIT.
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Figure   7 Schematic Representation of Human GIT
In GIT large intestine starts from the ileocecal  junction to the 
anus with a length of about 1.5 m (adults) and is divided into three 
parts  ,viz.,colon,  rectum and  the anal  canal.  The colon consists  of 
cecum,  colon  ascendens,  colon  transvesale,  colon  descendens  and 
sigmoid  colon.  Colon  is  made  up  of  four  layers,  serosa,  mucularis 
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externa, submucosa and mucosa. The serosa is the exterior coat of the 
large intestine and consists of areolar tissue that is covered by a single 
layer  of  squamous  mesothelial  cells.  The  muscularis  externa  is 
composed of  the  major  muscular  coat  of  the  inner  circular  layer  of 
fibers that surrounds the bowel and an outer longitudinal layer. Colonic 
longitudinal muscle fibers are composed of three flat long bands called 
taenia coli, which is shorter than other coats of the colon and hence 
results in wall contractions and formation of haustra. The submucosa is 
the layer of connective tissue that lies immediately beneath the mucosa 
lines  the  lumen of  the  colon  and  is  divided  into  epithelium,  lamina 
propria and muscularis  mucosae. The blood capillaries and lymphatic 
vessels supply biofluids to lamina propria.
Table 2  Properties of GIT
Properties  of 
GIT
Measured 
values
Microbial  metabolic  and 
enzymatic reactions in human GIT
Surface area
Total GIT
Resting volume
Stomach
Length
Total GIT
Duodenum
Jejunum
Ileum
Colon
pH
Stomach
Duodenum
Jejunum
2-106 cm2
25-50ml
500-700 cm
20-30 cm
150-250 cm
200-350 cm
90-150 cm
1-3:5
5-7
6-7
7
Hydrolysis of glucuronides, 
hydrolysis of glycosides, Hydrolysis 
of -CO-NH-compounds (amide, 
glycine  Conjugates and N-acetyl 
compounds), hydrolysis of esters 
Hydrolysis of sulfamates, 
dehydroxylation (C-dehydroxylation 
(O-demethylation, N-demethylation 
and other)dehalogenation, 
hetrocyclic ring fusion, reduction of 
double bonds, reduction of double 
bonds, reduction of nitro group,=s, 
reduction of azogroups, reduction of 
aldehydes, reduction of ketones, 
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Ileum
Colon
Rectum
5.5-7
7
reduction of alcohols, reduction of N-
oxides, reduction of aresenic acids 
aromatization, nitrosamine 
formation, acetylation & estrification
FACTORS GOVERNING THE COLON DRUG DELIVERY
PHYSIOLOGICAL FACTORS
Gastrointestinal Transit
The drug delivery systems first  enter  into  stomach and small 
intestine via mouth and then reach colon. The nature and pH of gastric 
secretions  and  gastric  mucosa  influence  the  drug  release  and 
absorption. In order to successfully reach colon in an intact form, the 
drug delivery system should surpass the barriers in the stomach and 
small intestine.
Small Intestinal Transit
Normally,  the  small  intestinal  transit  is  not  influenced  by  the 
physical state, size of the dosage form and the presence of food in the 
stomach. The mean transit  time of the dosage form is about 3-4 h. 
Colonic Transit
The bioavailability of drugs, released from the dosage forms can 
be highly  influenced by the colonic  transit  time.  Various factors like 
gender and size of the dosage form, and physiological conditions such 
as stress,  presence of food and disease state influence the colonic 
transit time.
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Gastric Emptying
Generally, in fasted state, gastric emptying is fastest and most 
consistent. Emptying completes from 5-10min upto 2 hours, depending 
on the phase of the stomach at the time of the drug administration. 
Gastric emptying can be considerably slowed by fed state. 
Stomach and Intestinal pH
Generally,  the  release  and  absorption  of  orally  administered 
drugs are influenced by the gastrointestinal pH. The pH gradient in the 
GIT is not in an increasing order. In stomach the pH is 1.5-2 and 2-6 in 
fasted and fed conditions, respectively. The acidic pH is responsible for 
the degradation of various pH sensitive drugs and enteric coating may 
prevent it. In small intestine, the pH increases slightly from 6.6-7.5 and 
decreases to 6.4 in right colon.
The pH of mid colon and left colon is 6.6 and 7.0 respectively. 
Since  there  is  minimal  variation  in  the  pH  from  ileum  to  colon, 
apparently  pH  dependent  polymer  drug  delivery  may  not  be  much 
selective. 
Colonic Absorption 
The surface area of the colon is much less compared to small 
intestine,  and  hence  not  ideally  suited  for  absorption.  Despite  this 
limitation,  the  colon  is  considered  for  drug  delivery  because  the 
environment  is  devoid  of  endogenous  digestive  enzyme  other  than 
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from microbial  origin and residents time of colon can be as long as 
10-24 hours. 
Figure 8 Absorption of drugs from colon and mechanism of 
absorption enhancers.
Drug molecules pass from the apical to basolateral surface of 
the epithelial cells by figure 8
1. Passing through colonocytes (transcellular transport),or
2. Passing  between  adjacent  colonocytes  (paracellular 
transport)
Gastrointestinal disease state
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General  intestinal  diseases  such  as  IBD,  Crohn’s  disease, 
constipation, diarrhea and gastroenteritis may affect the release and 
absorption  properties  of  colon  –specific  drug  delivery  systems,  
Table 3. Most  of the diseases associated with nausea and vomiting 
may  expel  the  drug  content.  In  antibiotic-  related  colitic  condition, 
plaque formation on the mucosa may interfere with the absorption of 
drugs.
Table 3   GIT Diseases which affects the Performance of 
Colon-Specific Drug Delivery Systems
Inflammatory Bowel 
Diseases (Crohn's 
disease and ulcerative
colitis)
Diarrhea,  fever,  anemia,  obstruction  of 
lymphatic  drainage  and  hyperplasia  of 
lymphoid tissue, which are observed in this 
condition may affect the drug release and 
absorption.  The  inflammatory  response 
extends  from  mucosa  to  serosa  through 
intestinal  wall.  Impairment  of  lymphatic 
drainage causes malabsorption of fats and 
highly lipophilic dings. Thickening of mucosa 
and submucosa may reduce surface area 
and obstruct diffusion.
Diarrhea
Hypermotility  and  frequent  passage  of 
hypertonic  liquid  feces  significantly  affect 
drug absorption and release.
Antibiotic associated 
colitis
Overgrowth  of  Clostridium  difficile  and  its 
toxin  production,  which  alters  mucosal 
surface area, may reduce drug absorption.
Constipation
Decreased  peristaltic  movement  of  bowel 
decreases diffusion and availability of drug in 
absorption  sites.  Severe  constipation 
reduces bowel movement once or twice a 
week and interferes with the movement of 
formulations.
Gastroenteritis Diarrhea due to increased mucosal secretion 
may affect the performance of  formulations
GIT infections Diarrhea  due  to  colonic  protozoal  and 
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bacterial  infections  causes  extremely  low 
transit time and increased mucus production, 
interferes  with  localization  of  drug  and 
absorption. Toxins produced may obstruct 
diffusion process
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PHARMACEUTICAL FACTORS
Drug candidates
Drugs,  which  show  poor  absorption  from  the  stomach  or 
intestine including peptide drugs, are most suitable for colon specific 
drug  delivery  systems.  The  drugs  used  in  the  treatment  of  IBD, 
ulcerative colitis, diarrhea and colon cancer, are ideal candidates for 
local colon delivery. 
Drug Carriers
The selection of carrier for particular drug candidate depends on 
the physicochemical nature of the drug as well as the disease for which 
the system is to be used. The factors such as chemical nature, stability 
and  partition  coefficient  of  the  drug  and  the  type  of  absorption 
enhancer chosen influence the carrier selection. 
TARGETING APPROACHES TO COLON
Polymer Based Approaches
Biodegradable Matrix and Hydrogel Systems
The  inability  of  GIT  enzymes  to  digest  certain  plant 
polysaccharides is  taken as an advantage to  develop colon-specific 
drug delivery systems. The drug is embedded in the matrix core of the 
biodegradable  polymer  by  compressing  the  blend  of  active  drug,  a 
degradable polymer  and additives.  Various polysaccharides such as 
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pectin,  guargum,  chondrotine,  etc.  are  being  employed  for  colon 
targeting. 
pH sensitive polymer system
The mechanism of pH sensitive systems resembles the enteric 
coating  of  drugs  which  prevent  drug  release  in  stomach  whereas 
releases the contents in intestine and thus causes a delayed release. 
The ideal pH sensitive polymers in  Table 4 for colon drug delivery are 
able to withstand the acidic pH of stomach and proximal part of small 
bowel,  and  selectively  disintegrate  the  intestinal  pH,  preferably  in 
ileocecal junction. This process eventually avoids distribution of drug 
throughout  the  large  intestine  and  improves  the  efficacy  of  colon 
delivery systems.
Figure 9 Schematic representation of biodegradable Guargum 
Matrix System
Compressed core of 150mg
5-ASA in guar gum
2% release in stimulated
Gastric and intestinal fluid
93% release in pH 6.8 buffer
Containing rat cecal contents
Eudragit polymers are being used for development of colon drug 
delivery systems. Eudragit-LO and Eudragit SO are soluble at 
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pH 6 and 7, respectively, hence they are used to make acid-resistant 
film coating. These polymers were used to develop systems containing 
drugs such as salsalzine, insulin and quinolones.Eudragit  SO coated 
systems  showed  optimal  delivery  of  insulin  in  ileum  at  pH  7  and 
successfully  delivered  more  than  60%  of  sulphapyridine  in  colon. 
Partially methylated Eudragit-SO that is soluble in slightly higher pH 
aqueous media, can be effective for colon drug delivery.
Table 4 Some Properties of pH Sensitive and Biodegrable 
Polysaccharides
pH sensitive 
polymers Biodegradable polysaccharides
Polymer Threshold pH
Polysaccharides and 
its general use
Bacterial species that 
degrade 
polysaccharide
HPMC phthalate 4.6-4.8 Amylose (tablet excipient) Bacteroides
PVA Phthalate 50 6.0 Arabinogalactase (thickening agent) Bifidobacterium
HPMC phthalate 
50 5.2
Arabinogalactase 
(thickening agent) Bifidobacteria
HPMC phthalate 
55 6.4
Chitosan (absorption 
enhancing agent ) Bacteroides
Eudragit L - 100 6.6 Chitosan (absorption enhancing agent) Bacteroides
Eudragit  L 6.0 Chodroitin sulphate Bacteroides
Eudragit  S 6.8 Pectin (thickening agent)
Bifidobacterium,
Eubacterium
Shellac 7.2 Pectin (thickening agent)
Bifidobacterium,
Eubacterium
CA Trimellitate 4.8
Dextran (plasma 
expander)
Guar gum (thickening 
agent)
Xylan (Plant 
hemicellulose)
Bacteroides
Bacterioides, 
Ruminococcus
Bacteroides
Bifidobacterium
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Biodegradable Polymer Systems
The degrading property of enzymes produced by microflora of 
the colon, particularly azoreductase activity is taken as an advantage in 
developing  bacteria-  biodegradable  polymer  coated  drug  delivery 
systems. These systems deliver drugs to colon without releasing drugs 
in small intestine. 
Bioadhesive Polymer Systems
When a system is coated with bioadhesive polymer it adheres 
on the wall of GIT increases the residence time of the system, there by 
improving the absorption possibilities. Bio adhesive systems made up 
of   various  polymers  such  as  polycarbophils,  polyurethanes  and 
polyethylene oxide – polypropylene oxide copolymers showed better 
adhesion in vitro and to some extent in  vivo. 
Prodrug Based Approaches
A prodrug is a pharmacologically inactive derivative of a parent 
compound  that  requires  spontaneous  or  enzymatic  transformation 
within the body in order to release active drug and that has improved 
release  properties  over  the  parent  compound.  Prodrug  can  be 
designed to release drugs systematically in specific organs and tissues 
such as kidneys, brain, eyes, breast and skin. The choice of carrier is 
largely determined by the functional groups available on the drugs. 
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MICROPARTICULATE DRUG DELIVERY 
SYSTEMS(2,17,18,19,20)
Microencapsulation  techniques  have  emerged  in  the  past  63 
years,  following the discovery of complex coacervation of gelatin by 
Bungenberg  de Jong and Kaes.  The first  commercial  application  of 
encapsulation  was  by the  National  Cash Register  Company for  the 
manufacture of carbon less copying paper.
Microencapsules  developed  for  use  in  medicine  consist  of  a 
solid or liquid core material containing one or more drugs enclosed in 
coating. Microencapsules are often described by other terms such as 
coated granules, pellets or seeds, microspherules and spansules. The 
most  common  type  of  microencapsules  structure  is  mononuclear 
spherical. 
Figure  10 Structure of Microcapsule and Microsphere
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The term ’Microcapsule’  should be reserved for reservoir type 
devices  where  as  ‘microsphere’  are  monolithic  or  matrix  type 
microparticles.  The  particles  can  be  embedded  with  in  a  polymeric 
matrix in   a solid aggregate state or a molecular dispersion to form 
microspheres. The particles can be coated by a solidified polymeric 
develop to form microcapsules as shown in figure 10
Microspheres
-monolithic,  uniform  distribution  of  particles  or  a  molecular 
dispersion.
Microcapsules contain,
 Liquid contents, non- permeable, rigid membrane.
 Aqueous contents, semi permeable membrane.
 solid core, protective or release- controlling coating.
Custom Microencapsulation Design
 Broad size range of capsules: 100nm to 6mm
 Broad range of pay load: upto 95 percent.
CORE MATERIAL 
The core material, defined as the specific material to be coated, 
can be liquid or solid in nature. The composition of core material can 
be varied, as the liquid core can be including dispersed or dissolved 
material.  The  solid  core  can  be  a  mixture  of  active  constituents, 
stabilizers,  diluents,  excipients  and  release  rate  retardants  or 
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accelerators. The ability to vary the core material composition provides 
definite  flexibility  which  enables  design  and development  of  desired 
microcapsule properties.
COATING MATERIAL
Selection of the appropriate coating material dictates, to a major 
degree,  the  resultant  physical  and chemical  properties  of  the  micro 
capsules. The coating material should be capable of forming a film that 
is cohesive with the core material; be chemically compatible and non 
reactive  with  the  core  material;  and  provide  the  desired  coating 
properties such as strength, flexibility, impermeability, optical properties 
and stability.
Typical  coating  property  such  as  cohesiveness,  permeability, 
moisture sorption solubility, stability and clarity must be considered in 
the  proper  selection  of  microcapsule  coating  material.  The effective 
coating  thickness  varies  from tenths  of  a  micron  to  a  few hundred 
microns depending on the coating-to-core ratio and the particle size of 
the core material.
Examples of Shell Material
 Proteins
 Polysaccharides
 Starches
 Waxes
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 Fats
PURPOSE OF MICROENCAPSULATION
The process of microencapsulation enables as to achieve, 
a. Taste-making
b. Selective sorption
c. Sustained release
d. Reduced gastric irritation
e. Conversion of liquid to solid form for stabilization
f. Reduction of volatility 
g. Stabilization to oxidation
The final  product  form can  be  dry powder,  tablet,  capsule,  
dispersion, lotion or injectable.
METHODS OF MICROENCAPSULATION
Microencapsulation methods that have be or are being adapted 
to pharmaceutical use include,
1. Co acervation-phase separation
This technique of microencapsulation can be induced by 
a. temperature changes
b. incompatible  polymer addition
c. non-solvent addition
d. polymer-polymer interaction
2. Air suspension
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3. Spray drying and spray congealing
4. Pan coating
5. Solvent evaporation
6. Polymerization
7. Physical methods
a.  Multi-orifice centrifugal process
b. Electrostatic encapsulation
Southwest Research Institute (SwRI) having more than 
50 years of experience in microencapsulation and controlled release, 
has classified the methods of microencapsulation as;
 Spray drying
 Spray chilling
 Rotary disk atomization
Physical Methods of  Fluid bed coating
Encapsulation    Stationary nozzle coextrusion
 Centrifugal head coextrusion
 Submerged nozzle coextrusion
 Pan coating
 Phase separation
 Solvent evaporation
 Solvent extraction
Chemical methods of  Interfacial polymerization
Encapsulation  Simple and complex coacervation
 In-situ polymerization
 Liposome technology
39
 Nanoencapsulation
TECHNOLOGY  INVOLVED  IN  DIFFUSION  TYPE  RELEASE 
SYSTEMS
In these systems the release rate of drugs is determined by its 
diffusion through a polymer. There are basically two types of diffusion 
devices: reservoir devices, in which a core of drug is surrounded by a 
polymeric membrane, and matrix devices, in which drug is distributed 
uniformly in an inert polymeric matrix. Microspheres represent matrix 
type drug delivery systems whereas micropellets represent reservoir 
type systems.
Theoretically, controlled release of drugs from both capsule and 
matrix  type  drug  delivery  systems  are  controlled  by  Fick’s  law  of  
diffusion which defines the flux of diffusion Jd across a plane surface of 
unit area.
Jd = - D dc/dx
Where,
dc = diffusion of drug molecule in a medium of solid
dc/dx = concentration gradient of drug molecules across a 
diffusion path of thickness dx
The negative sign is used to define the flux of the drug in the 
action of decreasing the concentration. In the matrix type of drug very 
systems, the concentration gradient is time dependent and decreases 
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progressively in response to the growing thickness of diffusional dx  as 
time  goes  on.  In  these  systems,  the  drug  molecules  can  elute  out 
matrix through dissolution and then by diffusion through the polymer 
structure.
It is observed that dry solid in the layer close to the surface of 
the device are the first to elute and followed by that in the next layer. 
This is as shown in the figure 11 below.
Figure 11 Schematic Illustration of Controlled Release of Drug 
Molecules from Matrix type Drug Delivery Systems
Where,
A      = initial amount of drug solids impregnated in a unit volume
   of   polymer matrix
Cp    = Solubility of drugs in polymer phase
Cp    = Concentration of the drug at the polymer-solution interface
C      = Concentration of the solution in bulk of the elution solution
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δp     = Thickness of drug depletion zone in the matrix
δd  = Thickness of hydrodynamic diffusion layer device on the   
immediate surface.
δ(δp) = Differential  thickness of depletion zone formed after more 
drug solid elutes out.
In this model, it is assumed that the solid drug dissolves from 
the surface layer first; when this layer becomes exhausted of the drug, 
the next layer begins to be depleted by dissolution and diffuses through 
the matrix to the external solution. In this fashion, the interface between 
the regions was containing the dissolved drug and that containing the 
dispersed drug moves into the interior as a front.
Higuchi equation
This equation can be used to express the release rate from such 
systems.
Q = 
DE
T 2A−ECS Cst
x1 /2
Q = Drug released in g/ unit surface area
D =Diffusion coefficient of the drug
E = Porosity of the matrix
T =Tortousity of the matrix
Cs = Solubility of the drug in the release medium (g/ml)
A = Concentration of the drug in the dosage form
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Keeping all the parameters constant, Higuchi equation can be reduced 
to 
M = kt 1/2
Where, K is a constant.
The assumptions made in deriving the mathematical model are,
 A pseudo – steady state is maintained during release
 The total volume of the drug present per unit volume in the 
matrix is substantially greater than the saturation solubility of the 
drug per unit volume in the matrix i.e., excess solute is present.
 Drug  particles  are  much  smaller  in  diameter  than  the 
average distance of diffusion.
 The diffusion coefficient remains constant
 No interaction occurs between the drug and the matrix.
MECHANISM OF DRUG RELEASE FROM MICROPARTICLES
Drug release   from degradable micro spheres might give hints 
on the microstructure of particles and mechanism of erosion. The drug 
release is influenced by the structure of micro particles and properties 
of the biodegradable polymer itself.
Most of the drug delivery through microparticles exhibits a matrix 
type internal solid dispersion morphology structure. The drug may be 
insoluble  in  the  solid  matrix  and  the  drugs  are  released  by  a 
mechanism  that  involves  both  pore  diffusion  and  polymer  erosion. 
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Initially  water  diffuses  into  the  matrix  dissolving  the  drug  particles 
adjacent to the surface. The resulting osmotic pressure is relieved by 
forming  a  tarteous  channel  to  the  surface  and  releasing  a  defined 
amount of drug in the initial drug burst.
Figure  12  Release of drug from microspheres.
The burst effect is controlled mainly by 3 factors,
1. Drug polymer ratio
2. Particle size of dispersed drug
3. Particle size of microspheres.
As the penetrating water front continues to  diffuse into a micro 
particulate core , the dispersed drug particles are dissolved, creating a 
network  of  water  filled  pores  through which  the  drug diffuses in   a 
controlled manner, and hence the name, pore diffusion.
From gel  beads,  leakage of drug can occur as influenced by 
polymer concentration and mechanical treatments of beads. Physical 
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shaking produces more leakage than packed beads in a column. The 
open lattice structure, although a disadvantage in allowing leakage of 
small  proteins,  does  provide  high  porosity  for  large  substrates  and 
efficient exchange of substrates and products.  The polymer may be 
cross linked with  chitosan, polyacrylic  acid,  polyvinyl  alcohol, protein 
and  polyethylenimine  to  produce  more  stable,  lower  porosity 
complexes with improved leakage characteristics.
DELIVERY SYSTEMS FOR MICROSPHERES.21
For  commercial  use,  microspheres  should  be  placed  in 
pharmaceutically  acceptable  oral  delivery  systems  which  include 
tablets, capsules and dry powders for reconstitution into suspension. 
The  former  two  are  the  most  widely  used  oral  systems,  but  pose 
significant  technological  challenges  to  the  delivery  of  microspheres. 
Tablets are prepared by compression of spheres, and the compression 
forces  may deform and  fuse  the  microspheres  rendering  them into 
larger  aggregates.  Compression  forces  and  heat  generated  during 
compression may affect the stability of the encapsulated drug.
A  capsule  formation  although  providing  more  favorable 
manufacturing  conditions,  could  lead  to  chemical  instability  since 
capsule shells are made up of gelatin or starch. To maintain flexibility,  
they maintain  up  to  12% moisture  which  may promote  chances for 
hydrolytic  cleavage  of  the  biodegradable  polymer.  While  filling  into 
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capsules  or  compression  into  tablets,  minimize  fragmentation  and 
fusion of particles as both effects may alter the release properties.
BIODEGRADABLE POLYMERS AS CARRIERS FOR CONTROLLED 
RELEASE
The different  types  of  biodegradable  polymers  for  extended release 
preparations are given below.
• Natural
Albumin Collagen
Starch Chitosan
Dextran Casein
Gelatin Hemoglobin
Fibrinogen
• Synthetic
Poly (alkyl-cyanocrylate)
Poly (ethyl-cyanocrylate)
Poly (amino acids)
Poly (amides)
Poly (acryl amides)
Aliphatic Polyesters
Poly (malic acid)
Poly (glycolic acid)
Poly (hydroxyl butyrate)
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Poly (lactic acid)
Cross Linked Proteins and Hydrogels
Poly Vinyl Alcohols (PVA)
Cross-linked Poly Vinyl Pyrrolidone (PVP)
NON-BIODEGRADABLE POLYMERS
Poly Ethylene Vinyl Acetate
Poly Ether Urethane (PEU)
Cellulose Acetate (CA)
Poly Vinyl Chloride (PVC)
MICROSPHERE  PREPARATION  BY  SOLVENT 
EVAPORATION METHOD 22
A  wide  range  of  microencapsulation  techniques  have  been 
developed  to  date.  The  selection  of  the  technique  depends  on  the 
nature  of  the  polymer,  the  drug,  and  the  intended  use. 
Pharmaceutically  acceptable  microencapsulation  techniques  using 
hydrophobic  biodegradable  polymers  as  matrix  material  are  divided 
into four categories.
1. Emulsion-solvent evaporation (o/w, w/o, w/o/w)]
2. Phase separation (non solvent addition and solvent partitioning)
3.  Interfacial polymerization
4. Spray drying
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The solvent evaporation methods involves the emulsification of 
an organic solvent  (usually methylene chloride)  containing dissolved 
polymer and dissolve/ dispersed drug in an excess amount of aqueous 
continuous phase with the aid of an agitator. The concentration of the 
emulsifier present in the aqueous phase affects the particle size and 
shape. When the desired emulsion droplet size is formed, the stirring 
rate is reduced and evaporation of the organic solvent is realized under 
atmospheric  or  produced  pressure  at  an  appropriate  temperature. 
Subsequent  evaporation of  the dispersed phase solvent  yields  solid 
polymeric microparticles entrapping the drug. The solid microparticles 
are  recovered  from  the  suspension  by  filtration,  centrifugation  or 
lyophilization.  Phase  separation  is  a  non-aqueous  method  that  is 
suitable for encapsulation of water-soluble and water-insoluble drugs, 
generally used for encapsulation of peptides and proteins. In interfacial 
polymerization  a  capsule  shell  is  formed at  or  on  the  surface  of  a 
droplet or particle by polymerization. Spray drying is used to protect 
sensitive  substances  from  oxidation  based  on  the  atomization  of 
solution by compressed air and drying across a current of warm air.
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SOLVENT EVAPORATIONPROCESS
Single –Emulsion Solvent Evaporation
1. O/W Emulsion  Solvent Evaporation Technique
For  emulsion  solvent  evaporation,  there  are  basically  two 
systems from which to choose: oil- in- water (o/w) or water- in- oil (w/o).  
Oil- in – water emulsions are more widely used than w/o emulsions due 
to the  simplicity of the process and easy clean- up requirements for 
the final product.  In this process, both the drug and the polymer should 
be insoluble in water, while a water- immiscible solvent is required for 
the polymer. A schematic representation of o/w emulsification- solvent 
evaporation technique is shown in Figure 13 
In general, solvent evaporation method is particularly suitable for 
the microencapsulation of lipophilic drugs that can be either dispersed 
or dissolved in the dispersed phase of a volatile solvent. 
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Figure 13  Schematic representation of the preparation of PLGA 
microspheres by o/w emulsification/solvent 
evaporation technique
Formation of O/W Emulsion
CONTINUOUS PHASE
Aqueous Phase
H
2
O and Emulsifier 
(PVA, HPMC, MeC,
Gelatin, SO, Tween)
Evaporation of Organic Solvent
At atmospheric pressure
Vacuum
Heating
Washing and Drying
Collection of Microspheres 
Loaded with Active Substance
Filtration
Centrifugation
Decantation
Polymer
PLGA
PLA
Solvents
Methylene chloride
Chloroform
Dispersed phase
PLGA and Drug Mixed in
Organic phase
Drug in Co solvent
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2. Oil- in-oil emulsification- solvent evaporation technique
The major problem of the o/w emulsification technique is the low 
encapsulation  efficiency  of  moderately  water-  soluble  and  water- 
insoluble compounds. The drug can diffuse from the organic dispersed 
phase  into  the  aqueous  continuous  phase,  which  results  in  poor 
entrapping. Water- soluble drugs such as, theophylline, caffeine, and 
salicylic  acid  could  not  be  loaded  efficiently  using  an o/w emulsion 
method, whereas drugs with  low water  solubility such as diazepam, 
hydrocortisone,  and  progesterone  were  successfully  entrapped  in 
microspheres.
Oil-in-Oil (some times referred as water – in- oil) emulsification 
process was developed for the encapsulation of highly water- soluble 
drugs. In this technique, polymer and drug, contained in a polar solvent 
such as acetonitrile, are emulsified into an immiscible lipophilic phase, 
with light mineral oil commonly being used, in the presence of an oil- 
soluble surfactant such as Span.
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Table 5   Various formulation factors affecting microencapsulaion 
process and final product
1 Polymer
Concentration,composition(hydrophilicity/ 
hydrophobicity,amorphous crystalline),molecular 
weight,  uncapped  and  capped  terminal  end 
group.
2 Drug Nature and solubility
3. Solvent Nature (aqueous and non aqueous)
4. Emulsifier Nature and concentration
5.
Emulsification 
process
Temperature, stirring/ agitation speed, dispersed 
phase  Composition,  continuous  phase 
composition,  dispersed  Phase/  continuous 
phase ratio.
6 Drug / polyer ratio
7
Mode of 
solvent 
removal
However an important drawback of using and oil external phase 
is  cleaning up the  final  product.  The oil  has  to  be   removed using 
organic solvents such as n- hexane. Diphenylhydrmine hydrochloride 
mitomycin C, adriamycin,  cephadine and cefadroxin,  phenobarbitone 
and  timilol  maleate  are  some  examples  of  drugs  that  have  been 
encapsulated by this procedure.
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Figure 14  Various types of solvent evaporation methods
CONCLUSION
Emulsification/solvent  evaporation techniques offer a versatile, 
easy,  and  practical  method  for  the  manufacturing  of  biodegradable 
microspheres. This technique makes possible the entrapment of a wide 
range  drugs  having  different  physical  properties  and  solubility 
characteristics. It is possible to achieve various drug release profiles by 
the regulation of  copolymer  ratio,  molecular  weight,  and size of  the 
microspheres, drug loading, porosity and other formulation parameters. 
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NON-STEROIDAL ANTI INFLAMMATORY DRUGS 
NSAID's 12,13  ( A brief review)
In contrast to the opioid analgesics, the non opioid analgesics 
relieve pain without interacting with the opioid  receptors, they posses 
anti-  inflammatory  activity  and  are  known  as  Non-steroidal  anti 
inflammatory drugs (NSAID's). They reduce elevated body temperature 
and also posses uricosuric property to varying degrees and are non 
addicting.
Algesia (Pain) :  Algesia is an ill  defined unpleasant sensation 
usually evoked by an external or internal noxious stimulus.
Analgesic: A drug that selectively relieves pain without causing 
loss of consciousness.
MECHANISM OF ACTION
Mainly  by  inhibiting  the  biosynthesis  and  release  of 
prostaglandins.  This is  done by inhibiting the cyclooxygenase which 
results in the direct inhibition of the bio synthesis of prostaglandins and 
thromboxane  from  arachidonic  aicd.  There  are  two  forms  of 
cyclooxygenase, COX -1 which is constructive form of the enzyme and 
COX-2,  which  is  the form induced in  the presence of  inflammation. 
These  drugs  inhibit  COX-1  and  COX-2  enzymes  and  hence 
prostaglandin  synthesis.  They  are  chemically  classified  into  many 
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groups like salicylates, propionic acid derivatives, fenamates, oxicams 
etc.
NON - STEROIDAL  ANTI-INFLAMMATORY DRUGS ARE MAINLY 
USED FOR
I Colic Pain
II Ectopic Ossification
III Eye disorder (like scleritis)
IV Cystoid Macular Oedema
V Fever
VI Gout
VII Headache
VIII Kidney disorders (Proteinuria)
IX Malignant neoplasm
X Menstrual disorders
XI Migraine
XII Pain
CYCLOXYGENASE ENZYMES (COX -1 & COX-2)
Although  the  two  COX  enzymes  are  similar  in  their  physio 
chemical properties, they are distinctly regulated at both transcriptional 
and post transcriptional level.
The introns are   much larger in COX-1 genes than in the COX-2 
genes, accounting for length of 22- 23 kb and 8-9 kb respectively. The 
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Cox genes also differ in their promoters and transcripts according for 
the striking difference in their regulations.
Conventional NSAID's blocks COX -1 by hydrogen bonding to 
the arginin at 120 positions. At position 523 is an isoleucine molecule in 
COX-1 and valine in COX -2.  The smaller valine molecule in COX-2 
leaves a gap in the wall of the channel giving access to side pocket 
which  is  thought  to  the  site  of  binding  of  many  selective  COX-2 
inhibitors, (often sulfonyl-sulfono sulphonamide groups).
E.g. of COX   -   1  inhibitors - Aspirin & Aspirin like compounds
COX -  2  inhibitors-  Nimesulide, Meloxicam,
      Celecoxib, Rofecoxib
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SOLUBILITY-A PREVIEW 14
Combinational  chemistry,  Molecular  modeling  and  High 
throughput Screening have resulted in the discovery of various drug 
molecules with optimal receptor affinity but of poor biopharmaceutical 
characteristics.  It  often  results  in  very  hydrophobic  compounds with 
poor  solubility  which  can  drastically  reduce  productivity  in  drug 
discovery  &  development.  Drug  development  is  more  efficient  and 
robust  when  compounds  are  freely  soluble.  New  solubilization 
technologies will expand the number of New Chemical Entities (NCEs) 
that  can  be  formulated  to  meet  pharmacochemical  thresholds. 
Advances  in  particle  engineering,  encapsulation,  surface  property 
optimization and solubility enhancement are enabling the creation of 
new formulation of both new & existing compounds.
Influence of drug solubilization on business strategies
A  drug  should  be  soluble  at  physiological  site  to  be  readily 
delivered to the cellular membrane while  retaining their  hydrophobic 
properties. As growing number of new active compounds exhibit a very 
low solubility in biological media, the pharma industry is taking a major 
challenge to find routes to formulate such compounds in order to reach 
an acceptable bioavailability. Extra time & resources are necessary to 
develop  &  test  custom  formulations  for  poorly  water-soluble 
compounds. Though a pre-clinical formulation has been successfully 
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developed,  reformulation  may  be  required  to  obtain  a  formulation 
acceptable for clinical studies.
More than one-third of drugs listed in USP are poorly soluble. 
"Good"  or  "Bad"  solubility  depends  on  the  expected  dose.  For  an 
average  potency  of  1  mg/kg,  "Good"  solubility  should  be  at  least 
0.05g/L and "Bad" solubility should be less than 0.01g/L. The problem 
of poor solubility might 'be resolved by formulation development, but 
improvement of solubility by changing the molecule would be a better 
approach.
Drug solubilization technology
The  solubility  of  drugs  can  be  enhanced  by  the  following 
approaches
1.   Spray  drying  -  Here  the  solubility  of  the  insoluble  drug  is 
enhanced by encapsulating the drug particle with a hydrophilic 
polymer.
2.   Complexation  by  Cyclodextrins  -  Cyclodextrins  is  cyclic 
oligomers of  α-D-glucopyranose.  It  forms inclusion complexes 
with a host of compounds.
3.  Change in physical property - Solubility of lipophilic compounds 
is attributed due to this fact.
4.   Solubilization using cosolvents
5.    Emulsions  and  microemulsions  for  drug  Solubilization  and  
delivery.
6.   Micellization and drug solubility enhancement.
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7.   Liposomes in Solubilization.
8.   Using Pharmaceuticals salts.
9.   Prodrugs for improved aqueous solubility.
10. Solid dispersions.
11. Alteration of the solid state of the drug substance.
12. Particle engineering for enhanced bioavailability -Unique nano 
structured particles with  enhanced performance attributes can 
be obtained through the control of particle size, particle surface 
area and particle morphology.
13. Supercritical  Fluid  Processing  -  Includes  Supercritical  Fluid 
extraction, Supercritical Fluid Chromatography, and Supercritical 
Anti-Solvent processes (SAS).  In SAS a substance dissolved in 
a  liquid  is  precipitated  by  contacting  the  solution  with  a 
compressed gas in which the substance is sparingly soluble.
14. Porous Microparticles - Microparticles are useful in the delivery 
of a wide range of drugs. The suitability of microparticles for use 
in  drug  delivery  depends  on  a  variety  of  characteristics, 
including  size  and  porosity.  They  are  used  to  deliver  drugs 
intravenously so that they can pass safely the blood vessels, for 
increasing the surface area of a drug so that it will dissolve more 
rapidly.  Porosity  is  important  for  entrapping  gas  in 
micropraticles, for controlling the release rate of the drug from a 
microparticle.
15.  Starch derivatives and use of pharma grade resins.
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LITERATURE REVIEW
 Ghosh S 23, et al., studied Diclofenac sodium, a non-selective cyclo-oxygenase 
inhibitor  and etoricoxib,  a selective cyclo-oxygenase-2 inhibitor  have been 
widely used in treatment of patients with osteo-arthritis.  Five hundred and 
eighty-five  patients  with  uncomplicated knee osteo-arthritis  were  randomly 
allocated  into  3  equal  groups  and  received  either  diclofenac  sodium, 
etoricoxib  or placebo in a double-blind manner.  The response in both the 
drug groups was comparable and much more than placebo group. The study 
shows  that  etoricoxib  provides better  clinical  efficacy  and gastro-intestinal 
tolerability in osteo-arthritis in comparison to diclofenac sodium presumably 
due to the selective inhibition of cyclo-oxygenase-2  by etoricoxib.
 Patel HM, 24 et al., studied the binary system of etoricoxib with beta-cyclodextrin 
(beta-CD)  was  prepared  by  the  kneading  method.  Drug-cyclodextrin 
interactions in  solution  were  investigated  by the  phase  solubility  analysis. 
Differential  scanning  calorimetry,  infrared  spectroscopy,  powder  X-ray 
diffractometry  and  microscopic  study  were  used  to  characterize  the  solid 
state  of  all  binary  systems,  whereas  their  dissolution  properties  were 
evaluated according to the USP XXIII  paddle method. The results indicate 
partial  interaction  of  the  drug  with  beta-CD  in  the  physical  mixture  and 
complete interaction in the kneaded complex. The dissolution of etoricoxib 
was  notably  increased as  compared  to  pure  drug  as  well  as  its  physical 
mixture. The complex showed more than 75% drug released in 30 min.
 Chauhan B, 25 et  al.,  prepared  and  characterizes  solid  dispersions  of  poorly 
water-soluble drug etoricoxib using lipid carriers by spray drying technique. 
The  absence  of  etoricoxib  peaks  in  XRPD  profiles  of  solid  dispersions 
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suggests the transformation of crystalline etoricoxib into an amorphous form 
The in-vitro dissolution test showed a significant increase in the dissolution 
rate  of  solid  dispersions  as  compared  with  pure  etoricoxib,  spray-dried 
etoricoxib,  and physical  mixtures of  drug with lipid carriers.  Therefore,  the 
dissolution rate of poorly water-soluble drug etoricoxib can be significantly 
enhanced by the preparation of solid dispersions using lipid carriers by spray 
drying technique.
 Zhou HY, 26et al., used Ranitidine hydrochloride, as a model drug 
has done Water in oil in water (W/O/W) emulsion and solvent 
evaporation  methods  were  used  to  make  chitosan/  cellulose 
acetate  (CCA)  microspheres  sized  200  -  400  microm.  The 
loading efficiency and release rate of ranitidine were affected by 
chitosan  concentration  and  molecular  weight.  Microspheres 
smaller than 280 microm released the drug faster than did the 
bigger by about 10%. The optimal condition for the preparation 
of the microspheres was chitosan concentration 2%, molecular 
weight 1130 KD. The ranitidine release from the microspheres 
was 30% during 48 h in phosphate-buffer saline medium.
 Fundueanu G, 27 et  al.,  worked  about  the  transport  bioadhesive 
microspheres  loaded  with  DNA  to  intestine  and  to  test  their 
bioadhesive properties. Poly(vinyl  alcohol) (PVA) microspheres 
were prepared by dispersion reticulation with glutaraldehyde and 
further aminated. These microspheres were firstly loaded with 
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plasmid DNA by electrostatic interactions and then entrapped in 
cellulose  acetate  butyrate  (CAB)  microcapsules  for  gastric 
protection.  The  entrapped  PVA  microspheres  do  not  have 
enough force by swelling to produce the rupture of CAB shell, 
therefore  the  resistance  of  microcapsules  was  weakened  by 
incorporating  different  amount  of  the  pH/thermosensitive 
polymer  (SP)  based  on  poly(N-isopropylacrylamide-co-methyl 
methacrylate-co-methacrylic  acid)  (NIPAAm-co-MM-co-MA). 
This  polymer  is  insoluble  in  gastric  juice  at  pH  1.2  and  37 
degrees C, but quickly solubilized in intestinal fluids (pH 6.8 and 
pH 7.4).  Therefore,  DNA loaded PVA microspheres were  not 
expelled in acidic media but were almost entirely discharged in 
small intestine or colon. The integrity of DNA after entrapment 
was  tested  by  agarose  gel  electrophoresis  indicating  that  no 
DNA  degradation  occurs  during  encapsulation.  In  conclusion 
DNA  loaded  microspheres  were  progressively  discharged  in 
intestine.  The  integrity  of  DNA  was  not  modified  after 
entrapment  and  release,  as  proved  by  agarose  gel 
electrophoresis.  Both  loaded  and  un-loaded  aminated 
microspheres display good bioadhesive properties.
 Constantin  M,  28 et  al.,  prepared  Poly(vinyl  alcohol)  (PVA)  microspheres  by 
dispersion  reticulation  with  glutaraldehyde  and  further  aminated.  These 
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microspheres were firstly loaded with diclofenac (DF) and then entrapped in 
cellulose  acetate  butyrate  (CAB)  microcapsules  by  an  o/w  solvent 
evaporation technique for intestinal delivery of drug. The encapsulated PVA 
microspheres due to their low swelling degree in intestinal fluids, do not have 
enough  force  to  produce  the  disruption  of  CAB  shell,  therefore  different 
amounts of succinoylated pullulan microspheres (SP-Ms) (exchange capacity 
up to 5.2 meq/g) were co-encapsulated. The SP-Ms do not swell in acidic pH, 
but swell up to 20-times in intestinal fluids causing the rupture of CAB shell 
and facilitating the escape of loaded PVA microspheres.
 Varshosaz  J, 29 et  al.,  developed a  colon  specific  drug  delivery 
system for  Mezalazine  (5-ASA) cyclo-oxygenase inhibitor  and 
anti-inflammatory  drug  effective  in  Crohn's  disease  and 
ulcerative-colitis  which  is  rapidly  absorbed  from  Intestine. 
Coated chitosan microspheres were used for this purpose by an 
emulsion-solvent  evaporation  technique  based  on  a  multiple 
w/o/w  emulsion.  Four  hundred milligrams of  chitosan solution 
(3%) in dilute acetic acid (0.5 M) containing 12% 5-ASA was 
dispersed into 2 ml solution of cellulose acetate butyrate (CAB) 
in methylene chloride. The primary induced w/o emulsion was 
dispersed into a 1% PVA aqueous solution to produce a w/o/w 
multiple emulsion. From the dissolution studies microspheres of 
chitosan with medium Mw and 1 : 1 core/coat that showed the 
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greatest release of drug (near 80%) in the presence of caecal 
secretions with a zero-order mechanism
 Yang D, 30 et al.,  were prepared ,Oxidized cellulose acetate alkyl 
esters (OCAM, OCAOCT, and OCACET) by reacting oxidized 
cellulose  acetate  (OCA)  with  methanol,  octanol,  and  cetyl 
alcohol, respectively, using dicyclohexylcarbodiimide (DCC) and 
4,4’-  dimethylaminopyridine  (DMAP)  as  catalysts.  OCA  alkyl 
ester  microspheres  containing  5-FU  were  prepared  by  the 
emulsion-solvent  evaporation  method  using  CH2Cl2  as  a 
solvent  and  polyvinyl  alcohol  as  an  emulsifier.  Microspheres 
were  characterized  by  scanning  electron  and  confocal 
microscopies  and  powder  X-ray  diffractometry.  Dissolution 
studies were performed in pH 7.4 phosphate buffer-saline (PBS) 
at  37  ºC.  The  analysis  of  5-FU  was  performed 
spectrophotometrically by measuring absorbance at 286 nm. the 
new  oxidized  cellulose  esters  can  be  used  to  prepare 
biodegradable sustained-release microsphere formulations of 5-
FU. The release rate of the drug can be modified by changing 
the carbon chain length of the alkyl group.
 Anand  Kumar  Srivastava,31  et  al.,   studied   preparation  and 
evaluation  of  floating  microspheres  with  cimetidine  as  model 
drug  for  prolongation  of  gastric  residence  time.  The 
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microspheres  were prepared by the solvent evaporation method 
using  polymers  hydroxypropylmethyl  cellulose  and  ethyl 
cellulose.  The  shape  and  surface  morphology  of  prepared 
microspheres  were  characterized  by  optical  and  scanning 
electron microscopy, respectively.  In-vitro drug release studies 
were performed and drug release kinetics was evaluated using 
the  linear  regression  method.  The  prepared  microspheres 
exhibited prolonged drug release (-8 h) and remained buoyant 
for  >  10  h. In-vitro studies  demonstrated  diffusion-controlled 
drug release from the microspheres.
 Adi I, 32 et al., prepared Ibuprofen Microsperes using using cellulose 
acetate  by  emulsion-solvent  evaporation  method  using 
Polyethylene glycol was used as a surfactant at the ratio of 1:2:1 
for  drug:polymer:PEG.  The  microspheres  were  prepared  at 
three different speeds speeds (800, 1200, 1600 rpm), and were 
subjected  to  stability  studies  for  3  months  .  The  particles 
decreased with increasing stirrer speed. The physical properties 
and release profiles of ibuprofen microspheres did not change 
after storage under accelerated stability conditions for 3 months.
 Palmieri G F,33 et al.,   utilized polymers for gastroresistant film coating of tablets 
or  pellets  such  as  cellulose  acetate  
phthalate  (CAP),  cellulose  acetate  trimellitate  (CAT), 
hydroxypropylmethylcellulose  phthalate  (HPMCP),  and  Eudragit  L  and  S 
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were used in the preparation of drug/polymer matrix tablets. These tablets 
were  prepared  either  by  direct  compression  of  both  powders  or  by  the 
formulation of microspheres that were then compressed. The microspheres 
were  characterized  by  scanning  electron  microscopy  (SEM),  differential 
scanning calorimetry (DSC), and X-ray diffractometry analyses. Dissolution 
studies  were  finally  carried  out  to  verify  if  the  tablets  possessed 
gastroresistant  or  controlled-release characteristics.  Except  for Eudragit  L, 
the  polymers  can  be  used  under  certain  conditions  in  the  formulation  of 
modified-release tablets.
 Soppimath K S,34 et al., prepared microspheres loaded with two antihypertensive 
drugs  viz.,  nifedipine  (NFD)  and  verapamil  hydrochloride  (VRP)  using 
cellulose-based  polymers  viz.,  ethyl  cellulose  (EC)  and  cellulose  acetate 
(CA).  The  microspheres  were  characterized  for  their  particle  size  and 
distribution,  tapped  density  and  encapsulation  efficiency.  Smaller  sized 
particles  with  a  narrow  size  distribution  were  produced  with  EC  when 
compared to CA matrices. The microspheres were directly compressed into 
tablets using different excipients. The drug release from CA was faster than 
EC microspheres and, also, the VRP release was faster than NFD
 Bhardwaj S B,35  et al., were prepared microspheres of verapamil 
hydrochloride,  with  three  different  cellulose  esters  namely 
cellulose acetate (CA), cellulose acetate propionate (CAP) and 
cellulose  acetate  butyrate  (CAB)  by  emulsion-solvent 
evaporation method. Drug release from the microspheres was 
affected by the nature  of  polymer.  Mathematical  modelling  of 
drug  release  data  by  fitting  the  data  to  various  equations 
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revealed that the data did not fit the conventional Higuchi's and 
aker-Lonsdale's  models  for  drug  release  from  spherical 
matrices.  Instead,  the  data  fitted  the  log-probability  and  the 
Weibull models quite well
 Rodríguez M,36  et al.,   studied a multiparticulate dosage form consisting of  a 
hydrophobic  core  coated  with  a  pH-dependent  polymer  is  proposed  for 
colonic specific delivery of drugs. Different approaches for olon-specific drug 
delivery  have  been  studied  over  the  last  decade,  including  prodrugs, 
polymeric coating using pH-sensitive or bacterial degradable polymers and 
matrices. In this work, we present a new multiparticulate system to deliver 
active molecules to the colonic region, which combines pH-dependent and 
controlled  drug  release  properties.  This  system  was  constituted  by  drug 
loaded cellulose acetate butyrate (CAB) microspheres coated by an enteric 
polymer (Eudragit(R) S). Both, CAB cores and pH-sensitive microcapsules, 
were  prepared  by  the  emulsion-solvent  evaporation  technique  in  an  oily 
phase.  The  in-vitro  drug  release  studies  of  pH-sensitive  microcapsules 
containing the hydrophobic cores showed that no drug was released below 
pH 7.
 Goto S, 37 et al.,  reported that  microencapsulation of ketoprofen using Eudragit 
E, L and S (acrylic resins) was investigated. The preparation is based on the 
dispersion  of  acetone  containing  ketoprofen  in  liquid  paraffin.  Aluminium 
tristearate was used as an additive for the preparation of microcapsules. In 
the  preparation  of  microcapsules,  the  reproducibility  of  the  Eudragit  E 
microcapsule was better than that of Eudragit L and S microcapsules. The 
microcapsules obtained were  uniform and free-flowing particles.  From the 
phase  diagram  of  ketoprofen-Eudragit  E  or  S-aluminium  tristearate,  it 
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became clear that the region in which the spherical microcapsules ranging 
from  250  to  1000  microns  in  size  could  be  prepared  was  limited.  The 
dissolution patterns of ketoprofen from Eudragit  E, L and S microcapsules 
were dependent on the pH of the dissolution medium.
 Palmieri GF, 38 et al.,  were prepared  ketoprofen gastroresistant microspheres by 
spray-drying using common pH dependent polymers, such as Eudragit S and 
L, CAP, CAT and HPMCP. The long ketoprofen recrystallization time was a 
serious hindrance to the preparation of microspheres having a drug content 
higher than 35%.Acrylic polymers (Eudragit  L or S) are considerably more 
effective  than  the cellulosic  derivatives  CAP and CAT,  while  the HPMCP 
profile  is  in  an  intermediate  position.  In  HCl  0.1  N,  the  percentage  of 
ketoprofen released from the tablets is always close to zero, independently 
from the polymer used.
 Brahma N, 39  et  al., studied  the   potential  interactions  among a  model  drug 
(azathioprine; AZA), polymers and a divalent metal ion, which were utilized in 
the development of a novel multiparticulate formulation for colonic delivery. 
The  approach  involved  preparation  of  beads  by  ionotropic  gelation  of 
deacylated  gellan  gum (DGG)  in  the  presence  of  Ca2+ ions,  followed  by 
coating with Eudragit®S-100
 Kim B K,40  et al., prepared microspheres containing the anti-hypertensive drug, 
felodipine, by the emulsion solvent evaporation method (o/o) using acrylate 
methacrylate  copolymers,  Eudragit  RL  PO  and  Eudragit  RS  PO,  as  wall 
materials.  The  release  profiles  and  encapsulation  efficiencies  depended 
strongly on the structure of the polymers used as wall materials. The release 
rate  of  the  Eudragit  RS  PO  microspheres  was  much  lower  than  that  of 
Eudragit  RL  PO  microspheres.  Whereas  Eudragit  RL  PO  microspheres 
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followed the Higuchi rule, Eudragit RS PO microspheres exhibited a triphasic 
release profile. It  is concluded that drug release rate can be controlled by 
choice of polymer type.
 Krishnamachari Y, 41 et al., prepared a   microparticulate system consisting of 
non-enzymatically  degrading  poly(dl-lactide-co-glycolide)  (PLGA)  core  and 
delivering  budesonide  site  specifically  to  distal  ileum  and  colon  was 
developed. Budesonide-loaded microparticles were fabricated using solvent 
evaporation technique  and formulation  variables studied  included different 
molecular  weight  grades  of  PLGA  polymer  as  well  as  concentration  of 
polymer, surfactant and drug. Eudragit S-100, an enteric polymer, was then 
used  to  form  a  coating  on  the  surface  of  budesonide-loaded  PLGA 
microparticles  for  site  specific  delivery  to  the  distal  ileum and colon.  The 
budesonide-loaded PLGA microparticles coated with Eudragit S-100 coating 
showed a decrease in entrapment efficiency with an accelerated in-vitro drug 
release. Moreover, complete retardation of drug release in an acidic pH, and, 
once the coating layer of enteric polymer was dissolved at higher pH (7.4 and 
6.8), a controlled release of the drug from the microparticles were observed. 
From  the  results  of  this  investigation,  the  application  of  double 
microencapsulation technique employing PLGA matrix and Eudragit  S-100 
coating shows promise for site specific and controlled delivery of budesonide 
in Crohn's disease.
 Obeidat W M, 42 et al.,   investigated  Microencapsulation of the anti-inflammatory 
drug  piroxicam  and  the  anti-asthmatic  drug  theophylline  as  a  means  of 
controlling  drug  release  and  minimizing  or  eliminating  local  side  effects. 
Microspheres of both drugs that are different in the chemical nature and size 
were successfully encapsulated at a theoretical loading of 25% with the pH 
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sensitive  Eudragit  S  100  polymer  using  the  emulsion-solvent  evaporation 
method.  Both  preparations  exhibited  an  initial  rapid  release  in  the  acidic 
medium with theophylline showing a larger increase in the amount released 
during this stage. The drug release was sustained for both preparations at pH 
6.5 with theophylline microspheres, showing more extended release.  Drug 
release  rate  kinetics  followed  a  Higuchi  spherical  matrix  model  for  both 
microsphere preparations.
 Ali J, 43 et al., developed  microspheres for celecoxib to enhance its bioavailability 
by increasing its gastric residence time. Four different polymers-polyethylene 
oxide, Eudragit S, cellulose acetate, and Eudragit RL-were used to form the 
floating  microspheres  using  an  emulsion-solvent  diffusion  technique. 
Microspheres prepared with polyethylene oxide:Eudragit S:celecoxib (2:2:1) 
gave the best  in-vitro percentage release and was taken as the optimized 
formulation. By fitting the data into zero order, first order, and Higuchi model, 
it  could be concluded that the release followed first-order release kinetics. 
The correlation coefficient (R2 value) was obtained upon fitting the data to 
Higuchi equation, which signifies that the mechanism of release of celecoxib 
from the microspheres was diffusion rate-limited.
 Mura P,44 et al.,   developed a new colonic drug delivery system which takes 
advantage of the combined approaches of a specifically colon-biodegradable 
pectin  matrix  with  a  pH-sensitive  Eudragit  S100  polymeric  coating.  The 
developed system was able to suitably retard the onset of drug release and 
to provide a colon-specific delivery, thus overcoming the problems of pectin 
solubility in the upper gastrointestinal tract and low site-specificity of simple 
pH-dependent systems the importance of using appropriate dissolution test 
conditions to adequately characterize the drug release profiles from delivery 
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systems  endowed  with  a  microflora-activated  drug  release  triggering 
mechanism has been demonstrated.
 Shimpi S, 45 et al., evaluated the ability of polyglycolized glycerides 
(Gelucire)  in  protection  of  amorphous  form  of  drug  during 
compression  and  shelf  life  with  lower  proportion.  Amorphous 
etoricoxib  (AET)  was  prepared  by  spray  drying  technique. 
Tablets  of  AET  and  melt  granules  of  AET  (MG-AET)  with 
Gelucire  50/13  were  prepared.  Spray  drying  yielded  the 
amorphous etoricoxib.  Content  uniformity  in  the  tablet  was in 
between 95 to 105%. Other parameters like disintegration and 
hardness  were  well  within  the  limits.  The  results  showed 
significant difference in the degree of crystallinity between AET 
tablet and MG-AET tablet. MG-AET tablet showed absence of 
crystallinity  after  3  months  storage.  The  reason  could  be 
formation of hydrogen bonding between the Gelucire and AET. 
Gelucire  yielded  a  soft  embedding  during  tableting,  which 
prevented  the  polymorphic  transformation.  Polyglycolized 
glycerides  are  able  to  protect  amorphous  etoricoxib  during 
compression with less amount .
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SCOPE AND PLAN OF WORK
Research, development and sale of drug delivery system are at 
a rapid place throughout the world. This world guide trend will intensify 
in the next decades as cut in public health expenses demand lower 
cost  and  efficiency.  To  meet  this  demand,  many  efficient  drugs 
currently in use will be reformulated with delivery systems that can be 
value added for optimal molecular activity.
The main objective of  any drug therapy is to  achieve a drug 
therapy  in  the  desired  concentration  of  the  drug  in  blood  or  tissue 
which is therapeutically effective and non-toxic for an extended period 
of time. Controlled release technology has rapidly emerged over the 
past three decades as a new interdisciplinary science that offers novel 
approaches to micro particulate dosage form for bioactive agent. So far 
natural and synthetic polymers were employed to attain control  over 
release  pattern  of  the  drug,  unlike  synthetic   polymers,  natural 
polymers which are polysaccharides have the advantage to better bio 
compatibility  and  
non-toxicity.  Microencapsulation  is  a  technique that  can be used to 
formulate a sustained release system for a drug.
Colon  -  specific  delivery  can  be  achieved  with  as  suitable 
mechanism that triggers off the drug release upon reaching the colon. 
The physiological changes in the pH of the gastrointestinal tract have 
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been extensively exploited to convey the actives to the colon. Method 
based on pH sensitive delivery, such as delayed - onset dosage forms, 
could  be  a  simple  and practical  means for  colon  targeting.  The pH 
sensitive systems prevent drug release in stomach, whereas releases 
the  contents  in  intestine  and  thus  causes  a  delayed  release.  The 
polymers should withstand the acidic pH of stomach and proximal part 
of small bowel and selectively disintegrate in intestinal pH, preferably in 
ileocecal junction.
Polymers like Eudragit SO, Eudragit LO, and Eudragit S 100 etc. 
are used which are soluble at pH values  higher than 7. The pH of the  
colon of the normal subjects drops from 7.5 ±  0.4 in the terminal ileum 
to 6.4 ±  0.6 in the ascending colon. To avoid the release of drug in the 
terminal ileum rather than in colon is by using two polymers i.e. pH 
sensitive  and  also  other  imparting  a  controlled  release  property. 
Eudragit S was used to prevent the drug release till  the formulation 
reaches  the  terminal  ileum,  whereas  cellulose  acetate  avoided  the 
complete release in the ileum and effectively conveys the drug to the 
colon.
The drug used in the study was Etoricoxib, which is Cycloxygenese- II 
inhibitor.  The daily dose of etoricoxib is 60 mg to 120 mg the drug 
satisfies  all  the  criteria  needed  for  a  drug  to  be  formulated  into 
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sustained release system. In the study the method adopted for micro 
encapsulation was solvent evaporation technique.
The work has been planned in 5 stages namely
1. Development of calibration curve
2. Compatibility evaluation between drug and carrier.
3. Preparation of cores with cellulose acetates containing the 
drug.
4. Coating of the prepared cores with the polymer Eudragit S 
100.
5. In-vitro dissolution studies.
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Drug Profile 
ETORICOXIB 46, 47
1. STRUCTURE :
2. CHEMICAL NAME :  5-  CHLORO-2-[6-METHYL  PYRIN 
-3-Y]-3-[4-METHYL SULFONYL PHENYL]PYRIDINE 
3. PHARMACOLOGICAL CLASSIFICATION : 
CYCLOOXYGENASE II  INHIBITOR 
4. THERAPEUTIC CLASSIFICATION 
OSTEOARTHRITIS,RHEUMATOID ARTHRITIS
5. PROPERTIES: Off white crystalline powder , relatively insoluble 
in water and freely soluble in alkaline aqueous solutions 
6. MECHANISM OF ACTION : 
Etoricoxib is a non steroidal anti-inflammatory agent (dipyridinyl 
derivative) for oral administration.  It  is  a  selective  inhibitor  of 
cyclooxygenase-2 (COX-2) i.e. by the direct inhibition of the bio 
synthesis of prostaglandins and thromboxane from arachidonic 
acid.
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2
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N
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7. INDICATIONS AND DOSAGE 
7.1 Dental Pain : Single oral doses of 120mg have been effective 
Adult:  single  oral  doses  of  120mg  have  been  effective  in 
treatment of acute pain following dental surgery pain relief was 
not  greater  with  doses  of  180  or  240  mg.  In  these  studies, 
duration of action of at least 24 hours was reported with 120-mg 
doses. 
7.2 Dysmenorrhea
Adult:  Etoricoxib  was  more  effective  than  placebo  and  as 
effective  as  naproxen  sodium  for  relieving  pain  of 
dysmenorrhea. 
7.3 Osteoarthritis: Once daily doses of 30mg or 60mg have shown 
efficacy in patients with osteoarthritis of the knee. The 60 mg 
dose tended to be more effective than 30mg 
7.4  Rheumatoid Arthritis :   Oral  etoricoxib 90 or 120 mg once 
daily was effective in treating rheumatoid arthritis  
8. ADULT DOSAGE 
Normal Dosage 
Oral route 
1) Optimal  doses  have  not  been  clearly  established  in  any 
indication. 
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2) An oral dose of 120 mg has been effective in acute DENTAL 
PAIN; no additional benefit was seen with higher doses (180 or 
240 mg) 
3) In  RHEUMATOID ARTHRITIS,  90  or  120 mg once daily  has 
been effective 
4) Once-daily doses of 30 or 60 mg have shown efficacy in patients 
with OSTEOARTHRITIS of the knee. The 60 mg dose tended to 
be more effective than 30 mg; efficacy was similar with 60 and 
90 mg once daily 
9 PHARMACOKINETICS 
9.1  ADME 
9.1.1 Absorption 
A)  Bioavailability 
1) ORAL, TABLET: 80% to 100% 
a) In  one  study,  the  pharmacokinetics  of  etoricoxib  appeared 
similar with use of four different tablet formulations. 
b) Antacids (calcium carbonate, aluminum/magnesium hydroxide) 
do not significantly affect the absorption of etoricoxib 
B) Effects of Food 
1) Decreased  rate  of  absorption  but  no  effect  on  extent  of 
absorption 
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a) A 120mg dose administered after  a  high-fat  meal  resulted in 
36% lower C  max and a 2-hour delay in t max, but no change in 
AUC 
9.2 Distribution 
A) Distribution Kinetics 
1) Volume of  Distribution:  119 L at  steady state  following 24mg 
single intravenous dose 
9.3 Metabolism
 A)  Metabolism Sites and Kinetics 
1) LIVER, at least 90%  
a) The  major  metabolic  pathway  is  6'-methyl  hydroxylation, 
primarily  via  cytochrome  P450  (CYP)-3A4.  Other  metabolites 
include  the  1'-N-oxide,  6'-carboxylic  acid,  and  6'-hydroxylated 
glucuronide. 
9.4 Excretion 
A) Kidney  1)  Etoricoxib  is  excreted  in  the  urine,  primarily  as 
metabolites. 
B) Other 
1) OTHER EXCRETION 
a) TOTAL  BODY  CLEARANCE:  0.049  L/minute  following  25mg 
single intravenous dose 
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b) FEACES:  Etoricoxib  is  excreted  in  the  feces,  primarily  as 
metabolites.
10 CONTRAINDICATIONS AND PRECAUTIONS 
10.1  Contraindications 
A) Previous hypersensitivity to etoricoxib 
B) Acute peptic ulcer disease or GI bleeding 
C) Patients with a history of bronchospasm with rhinoconjunctivitis 
or  urticaria/angioedema  associated  with  aspirin  or  other 
nonsteroidal  anti  inflammatory  agents  (adult-onset  asthma, 
chronic rhinitis, nasal polyps, and chronic urticaria/angioedema 
predispose  to  these  reactions)  (risk  of  anaphylactic-like 
reactions) 
D) Severe renal or hepatic disease 
10.2 Precautions 
A) History of mild allergic phenomena related to ingestion of other 
non steroidal anti inflammatory drugs (e.g., rash) 
B) Conditions predisposing to gastrointestinal events (e.g., history 
of peptic ulcer, upper gastrointestinal disease, ulcerative colitis; 
smoking;  advancing  age,concurrent  aspirin  or  corticosteroids; 
alcohol abuse; stress) 
C) Patients  with  hypertension,  recent  MI,  angina,  or  other 
cardiovascular disease 
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D) Patients with bleeding disorders (potential exacerbation) 
E) Mild  or  moderate liver  disease (pharmacokinetic data lacking; 
enhanced risk of adverse events, such as fluid retention) 
F) Mild  or  moderate  renal  impairment  (pharmacokinetic  data 
lacking;  potential  for  adverse  renal  effects,  particularly  in  the 
elderly); there is no convincing evidence that COX-2 selectivity 
reduces the risk of renal toxicity relative to nonselective agents 
G) Patients  with  risk  factors  for  renal  failure  (e.g.,  diabetes, 
preexisting edema, hypovolemia, sepsis); there is no convincing 
evidence that COX-2 selectivity reduces the risk of renal toxicity 
relative to nonselective agents 
11. ADVERSE DRUG REACTIONS:
11.1 Cardiovascular system 
11.1a :  Small  increase  in  blood  pressure  have  been  reported  with 
doses of 60mg or 90 mg 
11.1b : Thromboembolic disorder
11.2 Gastrointestinal 
11.2 a Significantly  fewer  upper  gastrointestinal  events  and 
uncomplicated GI events with etoricoxib than with diclofenac in 
patients with osteoarthritis and rheumatoid arthritis.
11.2 b Nausea,  vomiting,  diarrhea,  heart  burn,  taste  disturbances, 
decreased appetite and flatulence 
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11.2 c Head ache, dizziness, fatigue and insomnia 
12. DRUG INTERACTIONS  
Drug –drug Combinations 
Cytochrome p 450 , isoenzyme cyp3A4 inhibitors or inducers , 
rifampicin  ,  ethyloestradiol,  oral  salbutamol,and  minidoxil. 
Antidepressants  SSRIs  and  Venlaflaxine  may  increase  risk  of 
bleeding .Risk of side effects increased with concomitant use of Aspirin 
,  cyclosporin,ketorolac  or  other  NSAID,  lithium  ,and  methotrexate  , 
coumarin ,phenytoin and sulphonyl  ureas .
Table-6
 MARKETED FORMULATION
PRODUCT DOSE DOSAGE MANUFACTER
EBOV 60MG TAB GLENMARK
90MG TAB GLENMARK
120MG TAB GLENMARK
ETOXIB 60MG TAB UNICHEM
90MG TAB UNICHEM
120MG TAB UNICHEM
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Polymer Profile
1.CELLULOSE ACETATE  48,49
1. Non proprietary Names
 BP: Cellulose acetate
 PhEur: Cellulosi acetas
 ESPNF: Celluliose acetate
2. SYNONYMS
Acetyl cellulose;cellulise diacetate;cellulose triacetate.
3. CHEMICAL NAME AND CAS REGISTERY NUMBER
 Cellulose acetate (9004-35-7)
 Cellulose diacetate (9035-69-2)
 Cellulose triacetate (9012-09-3)
4. DEFINITION
Cellulose acetate is partly or completely O-acetylated cellulose. 
It contains not less than 29.0 percent and not more than 44.8 percent 
of  acetyl  groups  (C2H3O)  calculated  with  reference  to  the  dried 
substance. The acetyl contents is not less than 90.0 percent and not 
more than 110.0 percent of that started on the label, calculated with 
reference to the dried substance.
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5. STRUCTURAL FORMULA
6. FUNCTIONAL CATEGORY
Coating agent; release agent; tablets and capsules diluent.
7. APPLICATION  IN  PHARMACEUTICAL  FORMULATION  OR 
TECHNOLOGY
Cellulose acetate is widely used in pharmaceutical formulations 
both in sustained – release applications and for taste masking.
 Cellulose  acetate  is  used  as  a  semi  permeable  coating  on 
tablets,  especially  on  osmotic  pump- type  tablets  and implants,  this 
allows  for  controlled,  extended release of  activity.  Cellulose acetate 
films in conjunction with other materials, also offer sustained release 
without the necessity of drilling a hole in the coating as is typical with 
osmotic pump systems.  Cellulose acetate and other cellulose esters 
have  also  been  used  to  form  drug-  loaded  microparticles  with 
controlled – release characteristics.
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O
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Cellulose acetate  films are  used  in  transdermal  drug delivery 
systems and also as   film coating on tablets  or  granules for  taste 
masking. For. e.g., acetaminophen granules have been coated with a 
cellulose acetate-  based coating  before  being  processed to  provide 
chewable  tablets.  Extended-  release tablets  can also  be formulated 
with  cellulose  acetate  as  a  directly  comprisable  matrix  former.  The 
release  profile  can  be  modified  by  changing  the  ratio  of  active  to 
cellulose acetate and by incorporation of plasticizer, but was shown to 
insensitive  to  cellulose  acetate  molecular  weight  and  particle  size 
distribution.
8. DESCRIPTION
Cellulose acetate occurs as a white to off- white powder, free 
flowing pellets, or flakes. It is tasteless and odorless, or may have a 
slight odor of acetic acid. 
Figure 15 Scanning electron microscopy of cellulose acetate
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Fig 15(a) Fig 15(b)
Fig 15(a) SEM:1
Excipient : Cellulose acetate,CA-398-10 NF
Manufacturer : Eastman Chemical Co. 
Lot No. : AC65280NF
Magnification : 60x
Voltage : 3kV
Fig 15(b) SEM 2
Excipient : Cellulose acetate, CA-398-10NF
Manufacturer: Eastman Chemical Co.
Lot No : AC65280NF
Magnification: 600 x
Voltage : 2kV
9. PHARMACOPEIAL SPECIFICATIONS 
Table 7 Pharmacopeial specifications
Test PhEur 2002 USPNF 20
Identification + +
Characters + -
Loss of drying ≤  5.0% ≤  5.0%
Residue on ignition ≤  0.1% ≤  0.1%
Free acid + ≤  0.1%
Heavy metals ≤ 10ppm ≤  0.001%
Micorbial contamination 1000/g -
Organic volatile impurities - +
Assay ( of acetyl groups) 29.0- 44.8% 29.0-44.8%
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10. IDENTIFICATION Prepare  a  1  in  10  solution  of  Cellulose 
Acetate, previously dried in dioxane. Spread one drop of solution on a 
sodium chloride plate,  place a second sodium chloride plate over it,  
and spread the specimen between the plates. Separate the plates heat 
them both  at  105˚  for  1  hour  and resemble  the  dried  plate;  the  IR 
absorption spectrum exhibits maxima only at the same wavelengths as 
that of a similar preparation of USP Cellulose Acetate RS, treated in 
the same manner.
11. TYPICAL PROPERTIES
Density (bulk) : typically  0.4g/  cm3 for 
powders.
Glass transition temperature : 1700-190˚C
Melting point : Melting range 230-300 ˚C
Solubility : The  solubility  of  cellulose 
acetate is greatly influenced by the level of acetyl groups present. In 
general,  cellulose  acetates  are  soluble  in  acetone-  water  blend  of 
varying ratios, dichloromethane- ethanol blends, dimethyl formamide, 
and dioxane. The cellulose acetates of higher acetyl level are generally 
more limited in solvent choice than are the lower-acetyl materials.
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Viscosity (dynamic) : Various  grades  of  cellulose 
acetate are commercially available that differ in their acetyl content and 
degree  of  polymerization.  They  can  be  used  to  produce  10%  w/v 
solutions in organic solvents with viscosities of  10-230 mPa s. Blends 
of cellulose acetates may also be prepared with intermediate viscosity 
values. 
12. STABILITY AND STORAGE CONDITIONS
Cellulose acetate is stable if stored in a well-closed container in 
a cool, dry place. Cellulose acetate hydrolyzes slowly under prolonged 
adverse  conditions  such  as  high  temperature  and  humidity,  with  a 
resultant increase in free acid content and odor of acetic acid.
13. ASSAY
A.  For cellulose acetate containing not more than 42.0 percent 
of acetyl groups.
To 2.000 g in a 500ml conical flask add 100ml acetone R and 
10ml of water R .Close the flask and stir with a magnetic stirrer until 
dissolution  is  complete.  Add  30.0ml  of  1  M  sodium  hydroxide  with 
constant stirring. Close the flask and stir with a magnetic stirrer for 30 
min.  Add 100ml  of  water  for  2  min.  and cool  to  room temperature. 
Titrate with 0.5M sulfuric acid using 0.1ml phenolphthalein solution R 
as  indicator.  Carry  out  a  blank  titration  .Calculate  the  percentage 
content of acetyl groups from the expression.
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4.305(n2 –n1)
(100-d) x m
d = loss on drying as a percentage
m = mass of the substance to the examined, in grams, 
n1 = number of milliliters of 0.5 m sulphuric acid used in the test,
n 2  =  number of milliliters of 0.5 m sulphuric acid  used in the  blank 
titration.
B. For  cellulose  acetate  containing more than 42.0  per  cent  of 
acetyl groups.
To  2.000  g  in  a  500ml  conical  flask  add  30ml  of  dimethyl 
sulphoxide R and 100ml of acetone R. Close the flask and stirrer with a 
magnetic stirrer for 16 h. Add 30 ml of 1M sodium hydroxide with a 
constant stirring. Close the flask and stir with a magnetic stirrer for 6 
min. Add 100ml of water R at 80˚C, washing down the sides of the 
flask, stir for 2 min, and cool to room temperature. Titrate with 0.5M 
hydrochloric acid using 0.1ml of phenolphthalein solution R. Add 3.5ml 
of 0.5M hydrochloric acid in excess, stir for 50min and allow to stand 
for 30min. Titrate with 0.5M sodium hydroxide until  a persistent pink 
color  is  obtained,  stirring  with  a  magnetic  stirrer.  Calculate  the  net 
number of milli equivalent of sodium hydroxide consumed, taking the 
mean  of  two  blank  titrations  in  to  consideration.  Calculate  the 
percentage content of acetyl groups from the expression.
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4.305 x n
(100-d) x m
d = loss of drying as a percentage 
m = mass of the substance to be examined in  grams,
n = net number of milli equivalent of sodium hydroxide
14. INCOMPATIBILITIES 
Cellulose acetate is incompatible with strongly acidic or alkaline 
substances.  Cellulose  acetate  is  compatible  with  the  following 
plasticizers: diethyl phthalate, polyethylene glycol, triacetin, and triethyl 
citrate
15. METHOD OF MANUFACTURE
Cellulose acetate is prepared from highly purified cellulose by 
treatment with acid catalysis and acetic anhydride
16. SAFETY
Cellulose acetate is widely used in oral pharmaceutical products 
and is generally regarded as a nontoxic and nonirritant material.
17. HANDLING PRECAUTIONS
Observe normal  precautions appropriate to the circumstances 
and quantity of material handled. Dust may be irritant to the eyes and 
eye protection should be worn. Like most organic materials in powder 
form,  these  materials  are  capable  of  creating  dust  explosions. 
Cellulose acetate is combustible.
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18. REGULATORY ACCEPTANCE
Included in the FDA Ingredients Guide (oral tablets)
19. RELATED SUBSTANCES
Cellulose acetate Phthalate.
20. COMMENTS
When solutions  are  being  prepared,  cellulose  acetate  should 
always  be added to the solvent,  not  the reverse.  Various grades of 
cellulose acetate are available with varying physical properties.
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PREFORMULATION STUDIES
Before  formulation  of  drug  substance  into  dosage  form,  it  is 
essentially  that  it  should  be  chemically  and  physically  characterized. 
Preformulation studies give the information needed to define the nature of 
the drug substance and provide a frame work for the drug combination 
with pharmaceutical excipients in the fabrications of a dosage form.
QUALITATIVE ANALYSIS 
1. Compatibility evaluation
One of the requirements for the selection of suitable polymers or 
carriers for pharmaceuticals formulation is its compatibility. The study was 
carried out by using as infrared spectrophotometer to find out if there is 
any possible chemical interaction between drug and polymers at different 
ratios.
Physical  mixture  of  the  drug  and  the  polymer  was  mixed  with 
400 mg of potassium bromide. This mixture was compressed to form a 
transparent pellet in a hydraulic press at 15 tons pressure. The pellet was 
scanned at 4000 to 400 cm-1 in a FT-IR spectrophotometer. Similarly IR 
spectra  of  the  drug  and  polymers  separately  were  also  recorded.  The 
physical mixture was preserved in air tight containers and the spectra were 
recorded at 1 and 2 months interval.
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IR Spectral Analysis
Using  FT-IR  410  PC  spectrometer  carried  out  the  compatibility 
studies between drugs and the polymers.
There was no appearance or disappearance of any characteristic 
peaks, which confirmed the absence of any chemical interaction between 
drugs and polymer.
-90-
Figure 17 IR Spectra of Etoricoxib
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Figure 18 IR Spectra of Cellulose Acetate
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Figure 19 IR Spectra of Eudragit S 100
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Figure 20 IR Spectra of Etoricoxib and Cellulose Acetate
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Figure 21 IR Spectra of Etoricoxib and Eudragit S 100
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Figure 22 IR Spectra of Etoricoxib,Cellulose Acetate and Eudragit S 100
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Figure 23 IR Spectra of Cellulose Acetate and Eudragit S 100
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2. Thin – Layer Chromatography 51
The  preliminary  identification  of  Etoricoxib  and  also  the 
microspheres was performed by TLC method.
Pre coated TLC plates : Manufactured by S.D. Fine Chem. Ltd.
Absorbent layer : Silica gel 60 G
Layer thickness : 0.10 mm
Size : 10 x 20 cm
Separation Technique : Ascending
Mobile phase : Chloroform: methanol: Toluene in the 
ratio 1:2:1:
Chamber saturation : The Chamber was lined on three sides 
and  saturated  for  30  minutes  with  the 
above mobile phase. 
Preparation of standard : Pure sample of Etoricoxib was dissolved 
in methanol.
Preparation of Test Sample : Sample of drug Etoricoxib was dissolved 
in methanol
Detection : Dark Violet Spot in UV 
 Rf  : Distance traveled by the solute spot
Distance traveled by the solvent front
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Table 8  Rf values of etoricoxib
Sl.No. Name of the
Sample
Color
Detected
Rf Values
1 Standard Drug Violet 0.606
2. Test Drug Violet 0.585
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ANALYTICAL METHODS FOR 
ETORICOXIB 
1. High Performance Liquid Chromatographic 53  
2. Reverse Phase High Performance Liquid Chromatographic  Method 54
3. Liquid  Chromatography-Tandem  Mass  Spectrometry  with  Electro 
spray Ionization  in Human Plasma 55
4. Liquid Chromatography-Mass Spectrometry Method in Human Plasma 
56 
5. High Performance Thin Layer  Chromatography 52 
6. UV/Visible Spectrophotometric Method 57 
The present study used UV spectrometric method by using JASCO 
- UV-530
STANDARD GRAPH OF ETORICOXIB 57
JASCO-UV-530  spectrophotometer  was  used  for  all  absorbance 
measurement .Stock solution of etoricoxib was prepared in methanol.
In the simple UV method aliquots of stock solution of etoricoxib 0.5-
2.5ml were transferred into series of 10 ml volumetric flask and the volume 
was made upto the mark with 0.1N NaOH solution .The absorbance of the 
resulting  solution  was  measured  at  284  nm against  the  reagent  blank 
(prepared similarly without the drug) .Calibration curve was prepared by 
plotting concentration Vs absorbance 
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1. Preparation of Stock Solution 
Solution A
100 mg of drug etoricoxib was dissolved in methanol and made up 
the volume with 100 ml volumetric flask to give 1000µg/ml 
Solution B
From this 10 ml was taken and made up the volume with 0.1 N 
NaOH to give 100 µg/ml.
2. Preparation of Various Concentrations
a. 5  µ g/ml Solution  ------  0.5 ml of  the stock 
solution B was made upto  volume  with  0.1  N  NaOH  in  a  10  ml 
standard flask
b. 10  µ g/ml Solution  ------  1 ml of the stock solution B was 
made upto volume with 0.1 N NaOH in a 10 ml standard flask 
c. 15  µ g/ml Solution  ------ 1.5 ml of the stock solution B was 
made upto volume with 0.1 N NaOH in a 10 ml standard flask 
d. 20  µ g/ml Solution  ------  2 ml of the stock solution B was 
made upto volume with 0.1 N NaOH in a 10 ml standard flask 
e. 25  µ g/ml Solution  ------ 2.5 ml of the stock solution B was 
made upto volume with 0.1 N NaOH in a 10 ml standard flask 
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Procedure:
Various concentrations  of etoricoxib in 0.1 N NaOH solution 5-25 
µg/ml were prepared as mentioned above .Absorbance of the solution was 
measured against reagent blank using UV-Visible spectrophotometer.  A 
standard  graph  was  plotted  between  concentration  Vs  absorbance.  A 
straight line passing through the origin was obtained .The same procedure 
was repeated with 0.1 N HCl and mixed phosphate buffer   pH 7.5 
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Table 9 Standard graph of etoricoxib in 0.1 N HCl
Sl.No
Concentration in
µ g/ml
Absorbance  at
284 nm
0 0 0.000
1 5 0.1910
2 10 0.3889
3 15 0.5901
4 20 0.7862
5 25 0.9881
Figure  24   Standard graph of etoricoxib in 0.1 N HCl
Standard graph of etoricoxib  0.1 N HCl
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Table 10 Standard graph of etoricoxib in pH 7.5
Sl.No
Concentration in
µ g/ml
Absorbance  at
284 nm
0 0 0.000
1 5 0.2012
2 10 0.3922
3 15 0.6025
4 20 0.7917
5 25 0.9612
Figure 25 Standard graph of etoricoxib in pH 7.5
Standard graph of etoricoxib pH 7.5 
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MATERIALS AND EQUIPMENTS
MATERIALS COMPANY/SOURCE
Etoricoxib Anglo French Drugs and Industries Pvt.Ltd
Cellulose Acetate Loba chemie Pvt.Ltd
Eudragit S100 Rohm Pharma, Darmstadt Germany, (Degussa 
polymers, Mumbai.)
Acetone Qualigens Fine Chemicals
Liquid paraffin  Light Fisher Ltd
Ethanol Jiangsu Huaxi International Trade Co.Ltd China 
Methanol Loba Chemie Pvt.Ltd
Span-80 Loba Chemie Pvt.Ltd
Sodium hydroxide Loba Chemie Pvt.Ltd
Whatmann filter
Paper no.1 Qualigens 
Equipments COMPANY/MODEL
Stirrer Remi  Motors 
UV visible 
Spectrophotometer
JASCO –UV- 530
Scanning Electron
Microscope
JSM 6400
Digital balance Denver Instruments XP-300
Dissolution apparatus Elecrto Lab 
Vacuum pump Gelmen Series  
Fourier Transform
Infra Red-
Spectrophotometer
JASCO FT IR 410
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METHOD OF PREPARATION
Microspheres  of  etoricoxib  are  prepared  by  solvent  evaporation 
method  by  using  two  different  polymers  like,  cellulose  acetate  and 
Eudragit S 100 to achieve colon specific drug delivery. The preparation is 
done by using different drug: polymer ratios like  1:1, 2:1, 4:1  which are 
called as core microspheres. These core microspheres are again coated 
with eudragit S 100 at different ratios to study the controlled release of the 
drug in colon. 
MICROENCAPSULATION TECHNIQUE58
By solvent evaporation technique
Preparation of cellulose acetate cores containing the drug.
Etoricoxib was dissolved in the polymer solution containing the core 
polymer i.e., cellulose acetate in acetone at (1% w/v) with different drug: 
polymer ratios like 1:1, 2:1 and 4:1. The polymer and drug containing the 
solvent is emulsified into an immiscible lipophilic phase, with mineral oil, in 
the presence of oil - soluble surfactant such as span-80. About 10ml of 
acetone  was  added  to  the  external  phase  to  produce  a  stable  o/o 
emulsion.
-106-
Procedures 
70 ml of liquid paraffin containing 1% w/w of span -80 is kept in a 
variable speed propeller stirrer for 2000 rpm. The drug-polymer solution in 
acetone  is  added  by  thin  drops  into  the  oil  phase  and  the  system  is 
maintained for stirring 3 hrs.  About  10ml of  acetone was added to  the 
system. After 3 hrs, the formed microspheres, were separated and washed 
with n-hexane and dried for 48 hrs in vacuum desiccator.
The  above  procedure  was  used,  for  microencapsulation  of  drug 
loaded  cellulose  acetate  cores  with  the  polymer.  The  cores  were 
suspended in 5 ml of ethanolic  solution of eudragit S 100 (10% w/v)  in 
different ratios of cores like 1:1, 2:1, 4:1 with core: coat ratios 1:2.5, 1:5 
and 1:7.5 respectively. The above polymer solution was emulsified in liquid 
paraffin containing span 80 (1% w/w). About 5 ml of ethanol was added in 
to  the  external  phase  .The  system  is  maintained  in  variable  speed 
propeller at 2000 rpm for 3 hrs. The formed microcapsules were separated 
and washed with n-hexane and dried for 48 hrs in vacuum desiccators.
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Table 11 Drug and polymer at different ratios
Code Drug :Polymer (cores)
Cr1 1:1
Cr2 2:1
Cr3 4:1
Code Core (Drug: Polymer) Core : Coat
Ct1
Ct2
Ct3
1:1
1:2.5
1:50
1:7.5
Ct4
Ct5
Ct6
2:1
1:2.5
1:50
1:7.5
Ct7
Ct8
Ct9
4:1
1:2.5
1:50
1:7.5
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EVALUATION OF ETORICOXIB MICROSPHERES
1. Compatibility studies by using  FT-IR 
2. Thin - layer chromatography
3. Drug content uniformity
4. Scanning electron microscopy 
5. In vitro dissolution studies 
A. QUALITATIVE ANALYSIS BY INFRA-RED SPECTROSCOPY 
Compatibility Studies 
Microspheres prepared at different ratios were mixed with suitable 
quantity  of  potassium  bromide  .About  100mg  of  the  mixture  was 
compressed  to  form transparent  pellet  in  a  hydraulic  press  at  15  tons 
pressure.  The  pellet  was  scanned  at  4000  to  400  cm-1 in  a  FTIR 
spectrophotometer.  The  microspheres  were  preserved  in  an  air  tight 
container and the spectra were recorded at 1 and 2 months interval.
There was no appearance on disappearance of any characteristic 
peaks, which confirmed the absence of any chemical interaction between 
drug and polymer.
Similarly IR spectra of the drug loaded cores were also recorded.
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Figure 26   IR Spectra of Cellulose acetate cores at ratio 1:1
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Figure 27   IR Spectra of Cellulose acetate cores at ratio 2:1
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Figure 28   IR Spectra of Cellulose acetate cores at ratio 4:1
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Figure 29 IR Spectra of Etoricoxib microspheres of 1:1 cores coated with 1:5 of eudragit S 100 
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Figure 30 IR Spectra of Etoricoxib microspheres of 2:1 cores coated with 1:5 of eudragit S 100 
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Figure 31 IR Spectra of Etoricoxib microspheres of 4:1 cores coated with 1: 5 of eudragit S 100 
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B. THIN - LAYER CHROMATOGRAPHY
The  preliminary  identification  of  Etoricoxib  and  also  the 
microspheres was performed by TLC method.
Pre coated TLC plates : Manufactured by S.D. Fine Chem. Ltd.
Absorbent layer : Silica gel 60 G
Layer thickness : 0.10 mm
Size : 10 x 20 cm
Separation Technique : Ascending
Mobile phase : Chloroform: methanol: Toluene 
in the ratio 1:2:1:
Chamber saturation : The Chamber was lined on three sides 
and  saturated  for  30  minutes  with  the 
above mobile phase. 
Preparation of test sample : Microspheres  were  crushed  and 
extracted with methanol.
Preparation of standard : Pure sample of Etoricoxib was dissolved 
in methanol.
Detection : Dark Violet Spot in UV 
Rf : Distance traveled by the solute spot
--------------------------------------------------
Distance traveled by the solvent front
Rf. Values are shown in table
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Table 12 Rf. Values of etoricoxib microspheres
Sl.No. Name of the
Sample
Color
Detected
Rf Values
1 Standard Drug Violet 0.606
2. Test Drug Violet 0.595
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C. DRUG CONTENT UNIFORMITY
Microspheres containing 10 mg equivalent weight of etoricoxib was 
accurately  weighed  and  dissolved  in  2  ml  of  acetone.  Acetone  was 
evaporated  by  keeping  in  mantle  at  low  temperature.  The  residue  left 
behind is dissolved in methanol and the volume made up to 10 ml. The 
above  solution  was  kept  for  1  hour.  The  contents  were  filtered.  The 
absorbance  of  the  filtrate  was  measured  at  284  nm  by  using  UV 
spectrophotometer. 
Microspheres were also extracted with 10ml of 0.1 N HCl. After 12 
hours, the solution was filtered using Whatmann filter No.1. From this 1 ml 
was diluted to 5 ml with the same 0.1 N HCl and the absorbance of the 
filtrate  was measured  against  the buffer as a blank at 284 nm using UV 
visible  spectrophotometer  .Similar  procedure  was  followed  for  the 
extraction with phosphate buffer of pH 7.5.
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Table 13 Drug Content uniformity
Formulations 
code
Cores(Drug: 
Polymer) Core : Coat
Drug Content 
(mg)
Ct1
Ct2
Ct3
1:1
1:2.5 9.3
1:5 9.5
1:7.5 9.58
Ct4
Ct5
Ct6
2:1
1:2.5 8.9
1:5 9.4
1:7.5 9.54
Ct7
Ct8
Ct9
4:1
1:2.5 9.6
1:5 9.52
1:7.5 9.0
D.  SCANNING ELECTRON MICROSCOPY 
The Surface morphology and internal structure of the products was 
observed by a scanning electron microscope.Microspheres were fixed on 
an aluminum stubs using a double sided tube , sputter coated with gold to 
make  the  surface  conductive  and  examined  under  microscope  .SEM 
photographs  were  taken  by  using  JSM  6400  Scanning  Electron 
Microscope   at  the  120x  magnification  at  room  temperature  .  SEM 
photographs are shown in figure.
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Figure 32 SCANNING ELECTRON MICROSCOPY   OF CELLULOSE 
ACETATE CORES  
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Figure 33 SCANNING ELECTRON MICROSCOPY   OF ETORICOXIB 
MICROCAPSULES COATED WITH EUDRAGIT S 100
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E. IN-VITRO DISSOLUTION STUDIES 58, 59
The  microspheres  were  evaluated  for  their  integrity  in  the 
physiological environment of stomach and small intestine under conditions 
mimicking mouth to colon transit. 
Dissolution studies of eudragit micro capsules were carried out in 
triplicate using USP XIII dissolution rate test Apparatus 
The microspheres were tested for drug release for 2 hrs in 
0.1 N HCl (900ml) as the average gastric emptying time is almost 2 hrs.
Weighed  quantities  of  micro  capsules  were  loaded  into  the  basket  of 
dissolution apparatus containing 0.1 N HCl.
-122-
Then the dissolution medium was replaced with mixed phosphate 
buffer pH 7.5 (900 ml) and tested for drug release till the end of the test i.e. 
for 10 hours .The temperature of the dissolution medium was maintained 
at 37+0.5˚C with a stirring speed of 100 rpm .Samples were withdrawn 
every hour filtered through Whatmann filter paper, diluted and analyzed 
spectrophotometrically.
The dissolution  studies  of  the  cellulose acetate  cores  were  also 
performed under same set of experimental conditions.
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Table 14 Dissolution studies of cellulose acetate cores
Sl.No. Time in hours
Percent of Drug Release from Cores
1:1 2:1 4:1
1 0 0.00 0.00 0.00
2 1 9.56 10.25 11.36
3 2 11.25 12.15 13.45
4 3 20.62 24.38 28.12
5 4 26.25 28.12 33.75
6 5 31.88 33.75 37.50
7 6 33.75 37.50 41.25
8 7 37.50 46.87 46.87
9 8 46.87 50.62 51.15
10 9 52.50 54.38 58.12
11 10 56.25 58.13 61.88
12 11 59.16 62.89 69.39
13 12 63.75 66.33 72.44
Figure 34 Dissolution studies of etoricoxib cores with cellulose 
acetate 
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Dissolution studies of Etoricoxib Cores at drug:polymer ratio of 1:1,2:1and 
4:1
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Table 15 Dissolution studies of Etoricoxib microspheres of 1:1 cores 
coated with Eudragit S 100 at different ratios 
Sl.No. Time in hours
Percent of Drug Release from 
microspheres
1:2.5 (Ct1) 1:5 (Ct2) 1:7.5(Ct3)
1 0 0.00 0.00 0.00
2 1 7.22 8.34 10.01
3 2 7.99 9.06 10.78
4 3 20.62 24.38 28.12
5 4 24.38 30.67 39.37
6 5 30.35 36.65 37.50
7 6 33.22 41.56 45.17
8 7 37.50 46.87 50.62
9 8 43.12 50.67 54.37
10 9 45.33 51.15 55.89
11 10 48.35 52.12 56.78
12 11 51.54 54.56 58.13
13 12 53.78 58.12 61.69
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Figure 35 Dissolution studies of Etoricoxib microspheres of 1:1 cores 
coated with Eudragit S 100 at different ratios 
Dissolution studies of Etoricoxib microspheres of 1:1 cores coated with Eudragit S 100 at different 
ratios 
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Table 16 Dissolution studies of Etoricoxib microspheres of  2:1 cores 
coated with Eudragit S 100 at different ratios
Sl.No. Time in hours
Percent of Drug Release from 
microspheres
1:2.5(Ct4) 1:5(Ct5) 1:7.5(Ct6)
1 0 0.00 0.00 0.00
2 1 8.05 9.11 10.56
3 2 9.67 10.45 11.89
4 3 21.33 26.13 30.23
5 4 26.12 32.09 34.67
6 5 33.35 39.12 40.99
7 6 35.12 43.16 45.84
8 7 40.67 49.90 51.34
9 8 45.89 53.07 56.44
10 9 48.45 56.14 58.12
11 10 50.67 59.77 61.98
12 11 54.05 60.68 63.75
13 12 57.12 61.66 65.62
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Figure  36  Dissolution studies of Etoricoxib microspheres of  2:1 
cores coated with Eudragit S 100 at different ratios
Dissolution  studies of Etoricoxib 2:1 ( 1:5), (1:2.5) and 1.75
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Table  17 Dissolution studies of Etoricoxib microspheres of  4:1 
cores coated with Eudragit S 100 at different ratios
Sl.No. Time in hours
Percent of Drug Release from 
microspheres
1:2.5(Ct7) 1:5(Ct8) 1:7.5(Ct9)
1 0 0.00 0.00 0.00
2 1 9.37 9.99 10.11
3 2 11.33 12.11 12.98
4 3 25.11 29.12 39.37
5 4 29.67 32.37 33.75
6 5 35.33 37.50 45.00
7 6 40.12 41.25 48.75
8 7 44.35 46.87 50.62
9 8 49.12 52.22 54.37
10 9 51.56 54.21 58.12
11 10 54.37 58.13 63.75
12 11 57.88 61.77 65.88
13 12 62.12 64.78 69.82
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Figure  37  Dissolution studies of Etoricoxib microspheres of  4:1 
cores coated with Eudragit S 100 at different ratios
Dissolution  studies of Eloricoxib 4:1 ( 1:5), (1:2.5) and 1.75
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RESULTS AND DISCUSSION
Microspheres of etoricoxib with different polymers were formulated 
with  objective  of  controlled  release  of  etoricoxib  for  the  site  specific 
delivery of drug to the colon. 
Microencapsulation  was  done  by  solvent  evaporation  technique. 
Microspheres  were  prepared  by  using  the  polymers  such  as  cellulose 
acetate  and  Eudragit  S  100.  Cellulose  acetate  cores  containing  the 
etoricoxib were prepared by emulsion solvent evaporation method, where 
the  organic  solution  containing  the  etoricoxib  and  cellulose  acetate  in 
acetone was emulsified into an external oily phase of liquid paraffin. For 
the formation of a stable emulsion, small amount of acetone is added to 
the  external  oily  phase  to  prevent  the  precipitation  and  also  to  avoid 
diffusion of the organic solvent to the oily phase.
The prepared microspheres were characterized for the interaction 
studies  like,  compatibility  evaluation  using  FT-IR,  TLC,  Drug  Content 
uniformity, SEM and in-vitro dissolution studies.
The preformulation studies  confirmed no interaction between the 
drug and polymers as there is no appearance or disappearance of any 
characteristic  peaks  .The  Rf  values  also  confirms  that  there  is  no 
interaction between drug and polymers used. The microspheres prepared 
have good spherical  geometry as it  is  clearly evidenced from scanning 
electron microscopic pictures. The selection of the dispersion medium is 
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an important factor for  obtaining spherical  shape of optimum size.  The 
cores have got a rough surface due to rapid solvent evaporation and quick 
precipitation of cellulose acetate during the formation of an o/o emulsion.
Since liquid  paraffin  is  used as  an organic  oil  phase with  same 
polymer  concentration.  i.e.  (1%  w/v  cellulose  acetate),  there  was  no 
significant difference in the emulsion globule size. 
The in-vitro release profile of cellulose acetate cores were studied 
in 0.1 N HCl and mixed phosphate buffer pH 7.5. The results are given in 
tables 14  and  in figure 34  . From the figure it was found that the cores 
were intact at 0.1 N HCl and having the etoricoxib release of only 9.56%, 
10.25% and 11.36% for 1:1, 2:1, 4:1 drug: polymer ratios respectively. But 
the  drug  release  was  found  to  be  slow  release  phase  followed  by  a 
controlled release in mixed phosphate buffer pH 7.5 with  a percentage 
release of 63.73%, 66.33%, and 72.44% for 1:1, 2:1 and 4:1 drug: polymer  
ratios respectively at the 12th hour.
The cellulose acetate cores were again microencapsulated with pH 
sensitive acrylic polymer, Eudragit S 100 which can dissolve only in above 
pH 7. Eudragit S 100 can protect the cellulose acetate core in the upper 
part of gastro intestinal tract, which could effectively control the drug at the 
target site.
The cellulose acetate cores were coated with different core to coat 
ratios like 1:2.5, 1:5 and 1:7.5 for each ratio of the cores. The prepared 
microspheres were subjected to in-vitro dissolution studies.
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Preformulation  studies  were  also  performed  with  coated 
microspheres which confirm no interactions with  the polymer and drug. 
The SEM photographs of the coated microspheres revealed the spherical 
size  of  the  microspheres  with  the  smooth  and  dense  surface.   The 
microcapsules were also subjected for drug content uniformity .There was 
no loss of drug during the microencapsulation.
The studies showed that microspheres exhibited pH sensitive and 
controlled  release  properties.  The  drug  release  depends  on  pH of  the 
dissolution medium and cellulose acetate levels in the microspheres. 
It  was observed from the figure 35, figure 36 and figure 37 that 
there  was no drug release from the formulation at 0.1 N HCl. At pH 7.5 
acrylic coat dissolves and releases the cellulose acetate cores which can 
effectively control the drug release till 12 th hour. From figure 35, figure 36 
and figure 37  it is shown that, the etoricoxib is getting controlled release 
till the end as the core: coat ratio increases, which assures to give a better 
therapeutic activity of the drug. 
 In  brief,  successful  delivery  of  the  drug especially  to  the  colon 
requires the protection of etoricoxib from being released in the stomach 
and in small intestine. In this study the polymer in the form of coating by 
using  microencapsulation  was  applied  over  etoricoxib  core  drug  and 
release studies were carried under conditions mimicking from mouth to 
colon.
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SUMMARY AND CONCLUSION
Colonic  drug  delivery  has  several  therapeutic  advantages.  The 
delivery of drugs to colon is of value in the systemic disease. Etoricoxib 
was chosen as an experimental drug to get successful colonic delivery, a 
drug needed to be protected from the environment of the upper GIT and 
then rapidly released in colon. The study was carried out in six stages.
1. Calibration curve of etoricoxib by UV spectrophotometric 
method.
2. Compatability between drug and polymers was evaluated 
by peak matching by FTIR spectroscopic method.
3. Preparation  of  cellulose  acetate  cores  containing 
etoricoxib.
4. Coating/microencapsulation  of  cellulose  acetate  cores 
with Eudragit S 100.
5. Evaluation of the above prepared microspheres by using 
FTIR, TLC, SEM, drug content uniformity.
6. In vitro dissolution of the formulated microspheres were 
evaluated in 0.1 N HCl buffer and mixed phosphate buffer pH 7.5 by 
using USP XIII dissolution apparatus.
The below facts derived from the work done lead to the following 
conclusion.
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 Microcapsules are capable of releasing etoricoxib to the 
colon.
 The  double  coated  microspheres  are  having  both  pH 
sensitive and control release properties.
 Based  on  the  studies  it  can  be  concluded  that  the 
etoricoxib has been protected from the physiological environment of 
stomach  and  small  intestine  and  thus  capable  of  improving  the 
pharmacological  actions  for  the  management  of  rheumatoid 
arthritis.
It is obvious from the above work that the study has engineered a 
drug delivery  profile  in  which  the  drug release is  controlled  to  a  great 
extent and that the formulation in therapy can minimize the untoward side 
effect thus improving patient compliance. The industrial application of this 
method could be very simple and rapid. 
Thus, finally etoricoxib is protected to be released in the stomach 
and  succeeded  in  its  release  in  colon  which  helps  to  improve  its 
anti inflammatory action and protect the stomach from gastric bleeding of 
COX-2  inhibitors  by  delivering  the  drug  directly  to  colon  by  using 
microencapsulation technique.
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